WO2008050341A2 - Novel psychotropic agents having glutamate nmda activity - Google Patents

Novel psychotropic agents having glutamate nmda activity Download PDF

Info

Publication number
WO2008050341A2
WO2008050341A2 PCT/IL2007/001296 IL2007001296W WO2008050341A2 WO 2008050341 A2 WO2008050341 A2 WO 2008050341A2 IL 2007001296 W IL2007001296 W IL 2007001296W WO 2008050341 A2 WO2008050341 A2 WO 2008050341A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
compound according
disorder
agent
disease
Prior art date
Application number
PCT/IL2007/001296
Other languages
French (fr)
Other versions
WO2008050341A3 (en
Inventor
Moshe Portnoy
Irit Gil-Ad
Avraham Weizman
Original Assignee
Ramot At Tel-Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel-Aviv University Ltd filed Critical Ramot At Tel-Aviv University Ltd
Priority to CN2007800480740A priority Critical patent/CN101636182B/en
Priority to JP2009534053A priority patent/JP2010507648A/en
Priority to EP07827270.5A priority patent/EP2077860B1/en
Priority to US12/447,381 priority patent/US8394790B2/en
Publication of WO2008050341A2 publication Critical patent/WO2008050341A2/en
Publication of WO2008050341A3 publication Critical patent/WO2008050341A3/en
Priority to IL198331A priority patent/IL198331A/en
Priority to US13/748,861 priority patent/US8828993B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention is generally in the field of pharmaceutical compositions and methods for the treatment of psychological and/or psychiatric diseases or disorders.
  • Glutamate is the most abundant excitatory amino acids in the central nervous system (CNS). Glutamate acts through a number of receptors that affect both fast and slow neurotransmission.
  • the fast ionotropic N-methyl-D-aspartate (NMDA), the amino- 3-hydroxy-5-rnethyl-4-isoxazole (AMPA), and the slow metabotropic kainate receptor are a series of G-protein coupled receptors.
  • the ionotropic NMDA receptors are excitatory which has binding sites for glutamate and glycine, and possess an important role in memory and in mood disorders.
  • mGluRs metabotropic kainate glutamate receptors
  • the anti-psychotic drugs are widely used in the treatment of central nervous system (CNS) psychotic , diseases and disorders, such as schizophrenia. These agents block generally dopamine receptors and are divided into typical and atypical classes; phenothiazines are, for example, typical antipsychotics and clozapine, olanzapine and risperidone are classified as atypical antipsychotics. It is well known in the art that typical neuroleptic agents induce extrapyramidal symptoms, which include rigidity, tremor, bradykinesia (slow movement), and bradyphrenia (slow thought), as well as tardive dyskinesia, acute dystonic reactions and akathasia.
  • Atypical antipsychotics cause minimal extrapyramidal symptoms and thus rarely cause tardive dyskinesias, akathasia or acute dystonic reactions.
  • the administration of atypical antipsychotic agents involves other side effects such as increase of body weight, mood disturbances, sexual disfunction, sedation, orthostatic hypotension, hypersalivation, lowered seizure threshold and, in particular, agranulocytosis.
  • Schizophrenia is a chronic, debilitating disease with significant morbidity and mortality that often requires antipsychotic pharmacotherapy for life.
  • Current therapy consists of neuroleptics of the typical and the atypical type which share a common anti- dopaminergic activity.
  • NMDA inhibition would lead to diminished GABAergic tone, which in turn will induce disinhibition of glutamatergic AMPA receptor resulting in excitotoxic neuronal damage and psychosis.
  • NMDA agonists such as glutamate
  • GLY glycine
  • Agents like D-serine and D-cycloserine (DCS) showed in some clinical studies an improvement of mainly primary negative symptoms of schizophrenia when used as adjuvants to conventional neuroleptics such as risperidone and olanzapine.
  • Sarcosine is a glycine transporter 1 inhibitor found efficacious in improving symptoms (negative and positive) of patients with stable chronic schizophrenia.
  • BBB blood brain barrier
  • Glutamate receptors subtype antagonists, agonists and partial agonists are target of intensive research.
  • the NMDA receptor antagonist memantine was developed for the treatment of Alzheimer's disease.
  • the partial agonist agent D-cycloserine was found to induce some antidepressant and anxiolytic activity in animal models and to improve mood, insomnia and appetite. It is suggested that its anxiolytic effect is related to increased learning and fear extinction. Yet, a significant antidepressant activity of D- cycloserine compared to placebo in men was not observed.
  • agents targeting both the ionotrophic and the metabotrophic receptors of glutamate are under different stages of development for the treatment of anxiety, depression, cognitive and motor disorders.
  • the present invention discloses novel Central Nervous System (CNS) active compounds, such as psychotropic agents, having anti-dopaminergic activity and ability to modulate glutamate N-methyl-D-aspartate (NMDA) receptor activity.
  • CNS Central Nervous System
  • Such agents are useful in the treatment of schizophrenia and bipolar depression, and in particular have the ability to alter the negative symptoms of schizophrenia.
  • Such novel agents are also useful in altering states of other mood disorders such as depression and anxiety, cognitive deficits, movement disorders and drug addiction.
  • a CNS active compound (herein a compound of the invention) conjugated to a modulator of the glutamate NMDA receptor.
  • the CNS compound conjugated as recited herein, as known to a person skilled in the art, is a therapeutic agent that acts at a site within the central nervous system, particularly within the brain.
  • CNS-active compounds include CNS depressants, CNS stimulants, and drugs that selectively modify CNS function, such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, anti-emetics, analgesic-antipyretics, certain stimulants, antidepressants, antimanic agents, antipsychotic agents, sedatives and hypnotics.
  • the CNS-active agents are not limited to agents that act solely within the central nervous system.
  • the compound of the invention is of the general formula L-M-V, wherein L is a CNS active moiety; M is a linker; and V is a modulator of the glutamate NMDA receptor.
  • the CNS active agent when part of a compound of the invention is referred to as a "CNS active moiety", signifying its conjugation to the linker, M, or the modulator of the glutamate NMDA receptor V.
  • a CNS active moiety signifying its conjugation to the linker, M, or the modulator of the glutamate NMDA receptor V.
  • the compound of the formula L-M-V may be schematically exemplified as shown:
  • Linker M may be conjugated to the CNS active moiety, L, via any atom of the CNS active moiety.
  • the conjugation to L may be through one or more of the native atoms of the CNS active compound, namely through one or more atoms selected, for example, amongst C, N, S, P, and O, of the CNS active compound (in its unconjugated form), or through a chemically modified part of the CNS active compound, provided that such a modification (necessary for the attachment of the linker M) does not alter or diminish the activity associated with the CNS active compound.
  • Linker M may be conjugated to the modulator of the glutamate NMDA receptor, V, through any atom of the linker.
  • the modulator is typically an amino acid or an amino acid derivative
  • conjugation to the amino acid or amino acid derivative is typically through the ⁇ -carbon atom of the amino acid or amino acid derivative, as demonstrated below.
  • the modification may be any such modification known to a person skilled in the art. Based on the description provided herein, the artisan would know how to chemically modify a CNS active compound for conjugation. For general synthetic methodologies, see for example Comprehensive Organic Transformations: A Guide to Functional Group Preparations, Richard C. Larock, 2 n Ed., John Wiley & Sons, Inc., 1999.
  • the bond between M and L and/or between M and V is non-hydrolysable, namely the linker M does not dissociate from either the CNS active moiety and/or the modulator of the glutamate NMDA receptor, V 5 under aqueous physiological conditions, hi some embodiments, the bonds between M and L and/or M and V are covalent. In some embodiments, only one of the bonds between M and L or M and V is a non-hydrolizable bond while the other is a hydrolizable bond.
  • both the bonds between M and L and between M and V are non-hydrolizable.
  • the CNS active moiety may be any one moiety derived from a CNS active compound selected from the classes typically referred to as CNS depressants, CNS stimulants, and drugs that selectively modify CNS function, such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, antiemetics, analgesic-antipyretics, stimulants, " antidepressants, antimanic , agents, antianxiety agents, antipsychotic agents, sedatives and hypnotics.
  • CNS depressants such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, antiemetics, analgesic-antipyretics, stimulants, " antidepressants, antimanic , agents, antianxiety agents, antipsychotic agents, sedatives and hypnotics.
  • the CNS active moiety is selected from an anti-depressant compound, an anti-psychotic compound, an anti-epileptic compound, anti-anxiety and a compound for treating a movement disorder.
  • the CNS active moiety is derived from an anti-depressant compound selected amongst anti-unipolar agents and anti-bipolar agents.
  • anti-depressant compounds are fluoxetine, fluvoxamine, desipramine, paroxetine and sertraline.
  • Non-limiting examples of anti-bipolar agents are remoxipride, alizapride, clozapine, olanzapine and quetiapine.
  • the CNS active moiety is derived from an anti-psychotic compound selected from clozapine, olanzapine, quetiapine, loxapine, risperidone, flupenthixol, thioridazine, chlorpromazine, perphenazine, fluphenazine, zuclopenthixol, spiperone, amisulpride, sulpiride, remoxipride and alizapride.
  • an anti-psychotic compound selected from clozapine, olanzapine, quetiapine, loxapine, risperidone, flupenthixol, thioridazine, chlorpromazine, perphenazine, fluphenazine, zuclopenthixol, spiperone, amisulpride, sulpiride, remoxipride and alizapride.
  • the CNS active moiety is derived from an antianxiety compound selected from fluoxetine, fluvoxamine, desipramine, paroxetine and sertraline.
  • the CNS active moiety is derived from a CNS active compound selected amongst monocyclic, bicyclic and tricyclic anti-psychotic agents.
  • Non-limiting examples of monocyclic agents are amisulpride, sulpiride.
  • Non-limiting examples of bicyclic agents are spiperone, remoxipride, alizapride.
  • Non- limiting examples of tricyclic agents are chlorpromazine, perphenazine, fluphenazine, zuclopenthixol, clozapine, olanzapine, quetiapine, loxapine, flupenthixol and thioridazine.
  • the CNS active moiety is derived from clozapine, olanzapine, or quetiapine.
  • CNS active moiety derived from signifies the conjugation of a CNS active compound, as defined and exemplified, to afford a conjugate form of the compound, namely a conjugate moiety having the linker conjugated thereto.
  • a CNS active moiety derived from clozapine is a compound of the invention in which L is clozapine, M is a linker conjugated to clozapine, and V is a modulator conjugated to M.
  • the linker M may or may not be present.
  • L is conjugated directly to V.
  • M is present and is typically a linear group conjugating L and Y through one or more atoms on each moiety.
  • the linear group is typically a chain of between 1 and 8 atoms having at least one atom selected from C, N, O and S.
  • M is selected from -NH-, -NH 2 + -, -O-, -S-, C 1 -C 8 - alkylene, C 3 -C 8 -cycloalkylene, -CH 2 -O-CH 2 , -(CH 2 ) n -O-(CH 2 ) n -, -(CH 2 -O) n -, and -(CH 2 CH 2 -O) n -, wherein said alkylene and cycloalkylene may optionally be substituted by one or more groups selected from C 1 -C 4 alkyl, C 2 -C 4 alkenyl, and C 2 -C 4 alkynyl, and wherein each of n, independently of each other, is an integer between zero and 3 (i.e., being 0, or 1, or 2, or 3).
  • the alkylene or cycloalkylene may be interrupted by at least one heteroatom selected from N, O and S or by at least one or more double or
  • the modulator of the glutamate NMDA receptor, V is typically an amino acid, or ester, or amide, or alkylated amine of said amino acid.
  • the amino acids are selected from glycinyl (derived from glycine), sarcosinyl (derived from sarcosine), serinyl (derived from serine) and cysteinyl (derived from cysteine).
  • the amino acids are esters or amides of glycinyl, sarcosinyl, serinyl and cysteinyl.
  • the modulator of the glutamate NMDA receptor is (lS,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) or a derivative thereof.
  • esters of the above amino acids are C 1 -C 6 esters such as methyl, ethyl, propyl, butyl and hexyl esters of glycinyl, sarcosinyl, and serinyl.
  • the amides may be of C 2 -C 6 acids (of the general formula C 1 -C 6 -COOH 5 wherein the C 1 -C 6 carbon moiety attached to the -COOH, from which the amide is derived, is an alkyl having between 1 and 6 carbon atoms).
  • the compounds provided herein may contain one or more chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures.
  • the amino acid moieties constituting the functional moieties of the glutamate NMDA receptor either the L- or D-form may be present.
  • amino acid refers to ⁇ -amino acids which are racemic, or of either the D- or L-configuration.
  • alkylene refers to an alkyldiyl functional group having two free valences carbon atoms, namely an alkyl group substituted at both ends.
  • Ci-Cg alkylene refers to such an alkyl group having between 1 and 8 carbon atoms.
  • cycloalkylene similarly refers to a cyclic alkyl being substituted at both ends.
  • Cj-C V alkyl refers to an aliphatic chain of between 1 and 4 carbon atoms, being substituted at one position only.
  • C 2 -C 4 alhenyl refers to a carbon chain having between 2 and 4 carbon atoms and at least one C-C bond being a double bond.
  • C 2 -C4 alkynyl refers to a carbon chain having between 2 and 4 carbon atoms and at least one C-C triple bond.
  • the CNS active compound is a tricyclic anti-psychotic agent of the general formula (A) and the CNS active moiety is derived thereform:
  • X is selected from -NH-, -O- and -S-;
  • Z and Z' are each independently selected from C 1 -C 4 alkyl and halide (I, Br, Cl and F). In some cases, each of the rings substituted by Z or Z' may he substituted by one or more of Z and/or Z 1 .
  • Z is a methyl group. In still further embodiments, Z' is a halide.
  • the tricyclic compound of formula (A) is selected from olanzapine, quetiapine, and clozapine, the structures of which are shown below and the CNS active moiety is derived from olanzapine, quetiapine, or clozapine:
  • olanzapine may be conjugated to a linker via any of the atoms shown with an arrow:
  • the compound of the general formula L-M-V is a compound of formula (I):
  • the modulator of the glutamate NMDA receptor, V is glycinyl, or an ester thereof, and the compound is of the formula (Ia):
  • M is selected from null, -NH-, -0-, -S-, Ci-C 8 -alkyl, C 3 -C 8 -cycloalkyl, -CH 2 -O- CH 2 -, -(CH 2 -O) n -, and -(CH 2 CH 2 -O) n -, n is an integer between 0 and 3, and R is selected from H and a C 1 -C 4 alkyl.
  • the linker is absent and exemplary compounds of the invention are herein designated Compounds 1 and Compound 2.
  • the linker contains at least one heteroatom selected from N, O and S.
  • the linker is a Ci-C 5 -alkylene containing at least one heteroatom.
  • the Q-Cs-alkylene is interrupted by an O atom and exemplary groups are -CH 2 -O-CH 2 , -(CH 2 -O) n -, and -(CH 2 CH 2 -O) n -, wherein n is an integer between 1 and 3 (i.e., 1 or 2 or 3).
  • Exemplary compounds of such a structure of formula (Ia) are the compounds herein designated as Compound 3 and Compound 4.
  • the modulator of the glutamate NMDA receptor is sarcosinyl, or an ester thereof or serinyl, or an ester thereof, and the compound is of formula (Ib):
  • M is selected from null, -NH-, -0-, -S-, Ci-Cg-alkyl, C 3 -C 8 -cycloalkyl, -CH 2 -O- CH 2 -, -(CH 2 -O) n -, and -(CH 2 CH 2 -O) n -, n is an integer between O and 3,
  • R and R' independently of each other are selected from H and a d-G t -alkyl, and R" is selected from H and -CH 2 OH.
  • R' is a Ci-C 4 -alkyl
  • R" is H and R is optionally different from H.
  • R" is -CH 2 OH.
  • the linker M is absent, R" is H and R' is selected from H and C 1 -C 4 -alkyl.
  • exemplary compounds of the invention are herein designated Compound 5 through Compound 10.
  • the linker, M is Q-Cs-alkylene containing a heteroatom selected from N, O and S.
  • the linker is a Q-Cs-alkylene interrupted by at least one O atom, such as -CH 2 -O-CH 2 , -(CH 2 -O) n -, and -(CH 2 CH 2 -O) n -, wherein n is as defined above.
  • O atom such as -CH 2 -O-CH 2 , -(CH 2 -O) n -, and -(CH 2 CH 2 -O) n -, wherein n is as defined above.
  • Exemplary compounds are herein designated as Compound 11 through Compound 13.
  • the present invention thus also provides any one of Compounds 1 through 54 listed in Table 1, a salt thereof, a prodrug thereof, and a stereoisomer thereof.
  • the present invention further encompasses active compounds which are based on mono- and bicyclic antipsychotic agents such amisulpride, sulpiride, spiperone, remoxipride, and alizapride.
  • active compounds which are based on mono- and bicyclic antipsychotic agents such amisulpride, sulpiride, spiperone, remoxipride, and alizapride.
  • Such compounds may be utilized as the CNS active moiety, L 5 in the general formula L-M-V.
  • the monocyclic anti-psychotic agent amisulpride may be conjugated to a linker at any one of the positions (others are also possible) shown with an arrow:
  • alizapride a bicyclic anti-psychotic
  • the compounds of the invention may be prepared following total synthesis from commercially available starting materials or intermediates. As demonstrated below, olanzapine derivatives were prepared step-wise from substituted thiophene. The synthesis of clozapine proceeded step-wise from a substituted benzene. Once the backbone of the active moiety was prepared, substitution with an appropriate group, constituting the linker and/or the modulator of the glutamate NMDA receptor, was possible. The quetiapine derivatives were prepared via total-synthesis or alternatively via direct alkylation of the free hydroxyl group of the quetiapine skeleton.
  • a CNS active moiety substituted with a modulator of the glutamate NMDA receptor modulator, V i.e., having the general formula L-V (M being absent); or a CNS active moiety substituted with -M-V (in case steps (i) and (ii) are sequentially followed); or
  • the intermediate is a precursor of L-M-V, being, for example, of the general structure L-M
  • the intermediate may be further reacted with an appropriate precursor of the modulator of the glutamate NMDA receptor to afford a compound of the general structure L-M-V.
  • the reactive precursor of a CNS active moiety, L 5 is a precursor of the CNS active moiety which may be modified, by methods known in the art, to afford a CNS active moiety conjugated to a linker.
  • the precursor may be one having a free amine group, an alcohol, a thiol, an aldehyde, a ketone, a carboxylic acid or an active carbon group, through which conjugation may take place.
  • the conjugation of the moiety to the linker may take place, depending on the specific reaction conditions employed, under such experimental conditions as would be known to a person skilled in the art, to afford one or more of the following: high yield, selectivity, preference to a single isomer, etc.
  • the compounds of the invention typically contain at least one basic atom or substituent, and thus are capable of forming a wide variety of different salts with various inorganic and organic acids.
  • such salts must be pharmaceutically acceptable for administration to animals (human and non-human)
  • the acid addition salts of the compounds of this invention are readily prepared by treating the compounds with equivalent amounts of a chosen mineral or organic acid in an aqueous solvent or in a suitable organic solvent, such as methanol or ethanol.
  • a suitable organic solvent such as methanol or ethanol.
  • the desired solid salt may then be readily obtained by, e.g., evaporation of the solvent.
  • the pharmaceutically acceptable acid forms of the compounds of the invention are obtained from non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bi-tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, andp-toluenesulfonate.
  • non-toxic acid addition salts i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate
  • Certain compounds of the present invention have at least one acidic group and are thus capable of forming base salts with various pharmaceutically acceptable cations.
  • Examples of such salts include the alkali metal or alkaline-earth metal salts and, particularly, the sodium and potassium salts.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of compounds of the present invention are those which form nontoxic base salts with the herein described acidic derivatives.
  • These particular non-toxic base salts include those derived form such pharmaceutically acceptable cations as sodium, potassium, calcium and magnesium, etc.
  • These salts can easily be prepared by treating the compounds of the invention having at least one acidic group with an aqueous solution containing the desired pharmaceutically acceptable cation, and then evaporating the resulting solution to dryness, in some embodiments under reduced pressure.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum production of yields of the desired final product.
  • prodrug derivatives of the compounds of the invention also relates to prodrug derivatives of the compounds of the invention.
  • prodrug refers to pharmacologically inactive precursors of a drug that may be converted into its therapeutically active form under physiological conditions in vivo, for example, when they undergo solvolysis, or enzymatic degradation in blood, or in cells, (See as background reference: The Organic Chemistry of Drug Design and Drug Action, Academic Press, San Diego, CA, 1992).
  • the term also encompasses any covalently bonded carriers, which release the active compound in vivo when administered to an animal.
  • Prodrug modifications of a compound often offer advantages of solubility, bioavailability, absorption, tissue compatibility, tissue distribution, or delayed release in the mammalian organism.
  • the prodrug derivatives of compounds of the invention have groups cleavable under metabolic conditions, for example, pharmaceutically acceptable esters, or amides, it is to be understood that such cleaving does not refer to cleaving of a bond between moieties L and M and/or V and M in the general formula L- M-V.
  • the cleavable groups being different from L, M and V can be cleaved enzymatically or non- enzymatically, or hydrolytically to the free hydroxy, carboy, or amino group of the active parent compound.
  • the prodrug may also be a reduced form, which is oxidized in vivo to the therapeutic compound, for example, an alcohol to a carboxylic acid.
  • the present invention provides compounds, salts thereof (being pharmaceutically acceptable or unacceptable), internal salts thereof, hydrates thereof, polymorphs thereof, prodrugs thereof and mixtures of any one form thereof.
  • Pure compounds may be obtained following methods of purification as known in the art.
  • specific isomers may be separated by means of classical separation techniques, such as chromatographic or crystallization methods, or by other methods known in the art, such as through, formation of diastereomeric salts, for example by salt formation with an enantiomerically pure chiral acid, or by means of chromatography, for example by using chromatographic materials modified with chiral ligands.
  • the compounds of the invention are modulators of the glutamate NMDA receptor.
  • modulator refers to the ability of compounds of the invention to affect (alter) the activity of the glutamate NMDA receptor.
  • the receptor may be over or under activated in response to treatment with one or more of the compounds of the invention.
  • the over- or under-activation of the receptor may be determined by e.g., a functional assay or other in vitro, in vivo, and/or ex-vivo tests such as those demonstrated hereinbelow or such as those known to a person skilled in the art.
  • the compounds of the invention are agonists, namely having the ability to activate the glutamate NMDA receptor, or partial agonists, namely only partially activating the receptor.
  • the compounds are antagonists, namely having the ability to block or arrest the activity of the glutamate NMDA receptor, or partial antagonist.
  • the present invention provides the use of at least one compound (or a salt, prodrug, or a stereoisomer thereof) according to the invention for the preparation of a composition.
  • the composition of the invention is a pharmaceutical composition, comprising also at least one pharmaceutically acceptable carrier, diluent or excipient.
  • the pharmaceutical composition of the invention may comprise one or more compounds according to the invention.
  • the compounds may be compounds of different classes (e.g., one compound being a tricyclic psychotropic and the other an antidepressant), the compounds may be salt forms of the same compound (e.g., one compound being a sodium salt of Compound 1 and the other a potassium salt of Compound 1), different compounds in different or same form (e.g., one may be a salt and the other may be an ester), in different or same concentrations, etc.
  • compositions of the present invention there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention.
  • suitable formulations for oral, aerosol, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal, and vaginal administration are merely exemplary and are in no way limiting.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
  • Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch.
  • Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodiumk talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
  • Lozenge forms can comprise a compound of the invention in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to a compound of the invention, such carriers as are known in the art.
  • an inert base such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to a compound of the invention, such carriers as are known in the art.
  • the compounds of the present invention can be made into aerosol formulations to be administered via inhalation.
  • aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • Fo ⁇ rmlations suitable for parenteral administration include aqueous and nonaqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, glycerol ketals, such as 2,2-dimethyl-l,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carboniers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adj
  • Oils which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
  • Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts
  • suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxy- ethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl- ⁇ -aminopriopionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (3) mixtures thereof.
  • the parenteral formulations will typically contain from about 0.5 to about 25% by weight of the compound of the invention in solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions ma3' contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • HLB hydrophile-lipophile balance
  • parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use.
  • sterile liquid carrier for example, water
  • Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
  • the compounds of the present invention may be made into injectable formulations.
  • the requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J.B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4 th ed., pages 622-630 (1986).
  • compositions of the invention may comprise at least one compound or a pharmaceutically acceptable salt or derivative thereof and in addition comprise a carrier. Additionally, the composition may comprise at least one drug selected from CNS depressants, CNS stimulants, and drugs that selectively modify CNS function, such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, antiemetics, analgesic-antipyretics, certain stimulants, antidepressants, antimanic agents, antipsychotic agents, sedatives and hypnotics.
  • CNS depressants such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, antiemetics, analgesic-antipyretics, certain stimulants, antidepressants, antimanic agents, antipsychotic agents, sedatives and hypnotics.
  • compositions of the invention may be administered to a subject, a human or non-human, via any of the administration routes disclosed hereinbefore.
  • the pharmaceutical compositions may be used in a treatment regime of a disease or disorder of choice, as known to a medical practitioner, hi some embodiments, the disease or disorder is a psychological or psychiatric disease or disorder.
  • the present invention also provides a use of a compound according to the invention in the treatment of a disease or disorder.
  • the invention further provides a method of treating a disease or disorder comprising administering to a subject in need thereof a compound or a composition according to the present invention.
  • said disease or disorder is a psychiatric disease or disorder. In some other embodiments, said disease or disorder is associated with modulation of the activity of the glutamate NMDA receptor.
  • diseases and disorders are diseases and disorders of the CNS, such as psychotic disorders, anxiety disorders, dissociative disorder, personality disorders, mood disorders, effective disorder, neurodegenerative disorders, convulsive disorders, boarder line disorders and mental diseases and disorders.
  • the disease or disorder is selected from Schizophrenia, bipolar disorders (and maintainance for bipolarity), psychotic depression, delussional disorders, conduct disorders, psychosis-induced dementia, organic psychosis, mood disorders, Torte's syndrome, depression, post-traumatic stress disorder, anxiety, panic disorder and Alzheimer's disease.
  • the invention further provides a method of modulating the activity of the glutamate NMDA receptor, said method comprising contacting a tissue (e.g., a CNS tissue) expressing said glutamate NMDA receptor with at least one compound or a composition according to the invention.
  • a tissue e.g., a CNS tissue
  • the tissue being contacted with the at least one compound or composition according to the invention may be a tissue extracted or removed from the body of the animal (ex vivo) or a tissue in the body of the animal (in vivo).
  • said activity is enhanced. In some other embodiments, said activity is decreased.
  • Also provided by the present invention is a method for modulating one or more biological and/or pharmacological pathways, whereby said modulation ensues the treatment of an at least one psychological and/or psychiatric disease or disorder or the preventing of such a disease or disorder, said method comprising administering to a subject an effective amount of a compound or a composition according to the present invention.
  • the term "effective amount” refers to an amount of a compound of the invention, or a composition comprising thereof which is effective in treating at least one disease or disorder as defined.
  • the amount must be effective to achieve the desired therapeutic effect as described, i.e., of the activity of the glutamate NMDA receptor, depending, inter alia, on the type and severity of the disease to be treated and the treatment regime.
  • the effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount.
  • an effective amount depends on a variety of factors including the affinity of the ligand to the receptor, its distribution profile within the body, a variety of pharmacological parameters such as half-life in the body, on undesired side effects, if any, on factors such as age and gender, etc.
  • treatment or any lingual variation thereof refers to the administering of a therapeutic amount of the compound of the invention or a composition comprising thereof which is effective to ameliorate undesired symptoms associated with a disease, to prevent the manifestation of such symptoms before they occur, to slow down the progression of the disease, slow down the deterioration of symptoms, to enhance the onset of remission period, slow down the irreversible damage caused in the progressive chronic stage of the disease, to delay the onset of said progressive stage, to lessen the severity or cure the disease, to improve survival rate or more rapid recovery, or to prevent the disease form occurring or a combination of two or more of the above.
  • Figs. IA-D show the open filed results following i.p. administration of Compound 1 at 12.5, 25, 50, 75 and 100 mg/kg (each point is the mean +/- SEM of 3-5 determinations).
  • Fig. IA shows the effect on distance moved;
  • Fig. IB shows the effect ion velocity;
  • Fig. 1C shows the effect on rearing frequency; and
  • Fig. ID shows the duration of the "not moving" periods.
  • Figs. 2A-D show (each point is the mean +/- SEM of 6 determinations) the dose- dependent effect of Compound 6 (PGW-5) on the motility of mice.
  • Fig. 2A shows the effect on distance moved;
  • Fig. 2B shows the effect on velocity mean;
  • Fig. 2C shows the effect on rearing frequency; and
  • Fig. 2D shows the total duration of the "not moving" periods.
  • Figs. 3A-C show the effect of oral administration of Compound 1 on the horizontal and vertical behavior of mice.
  • Fig. 3A shows the effect on the distance moved;
  • Fig. 3B shows the effect on velocity; and
  • Fig. 3C shows the effect on number ofrearings.
  • Figs. 4A-C show the effect of Compound 3 (PGW-7) (12.5, 25 and 50 mg/kg, each point is the mean +/- SEM of 6 determinations) in the open filed test.
  • Fig. 4A shows the effect on the distance moved;
  • Fig. 4B shows the effect on the total duration of "not moving" periods and
  • Fig. 4C shows the effect on the rearing frequency.
  • Fig. 5 shows the effect of Compound 1, olanzapine and D-serine (20mg/kg, p.o) on time spent in the center of an open filed and on frequency to the center.
  • Figs. 6A-B show the effect of Compound 1 (20mg/kg, p.o.) on amphetamine- induced hyperactivity as manifested by the total number ofrearings and climbings over a period of lhr (Fig. 6A) and the effect of Compound 1 (20mg/kg, p.o.) on number of head movements (Fig. 6B).
  • Figs. 7A-B show the effect of Compound 3 (PGW-7) (12.5, 25, 50 mg/kg, i.p.), amphetamine (2 mg/kg, i.p.) and a combination thereof in the Open field test on distance moved (Fig. 7A) and immobility total duration (Fig. 7B).
  • PGW-7 Compound 3
  • Fig. 7A shows the effect of Compound 3
  • Fig. 7B shows the effect of Compound 3 (PGW-7) (12.5, 25, 50 mg/kg, i.p.), amphetamine (2 mg/kg, i.p.) and a combination thereof in the Open field test on distance moved (Fig. 7A) and immobility total duration (Fig. 7B).
  • Figs. 8A-E show the effect of Compound 1 (PGW), MK-801 and a combination thereof in the open field test on the distance moved (Fig. 8A); velocity mean (Fig. 8B); strong mobility total duration(s) (Fig. 8C); “not moving” total duration (Fig. 8D); and rearing frequency (Fig. 9E).
  • Figs. 9A-D show the effect of Compound 1 (PGW-4) (administered i.p.) on inhibition of the hyperlocomotion effect of MK-801.
  • Fig. 9A shows the distance moved total;
  • Fig. 9B shows the velocity mean;
  • Fig. 9C shows the effect of Compound 1, MK- 801 and a combination thereof on hi zone frequency;
  • Fig. 9D shows the effect of Compound 1, MK-801 and a combination thereof on in zone total duration.
  • Figs. 10A-D shows the effect of Compound 3 (PGW-7) (12.5, 25 and 50 mg/kg, i.p.) on hyperactivity-induced by MK-801 (0.15mg/kg, i.p.).
  • Fig 1OA shows effect of Compound 3, MK-801, and a combination thereof on distance moved;
  • Fig. 1OB shows the effect of Compound 3, MK-801, and a combination thereof on "not moving" total duration;
  • Fig. 1OC shows the effect of Compound 3, MK-801, and a combination thereof on in-zone frequency (zone 3); and
  • Fig. 1OD shows the effect of Compound 3, MK-801, and a combination thereof on in-zone total duration.
  • Fig. 11 shows the effect of Compound 1 (PGW) (30, 40 and 50 mg/kg, i.p.) on catalepsy.
  • PGW Compound 1
  • Figs. 12 A-D show the effect of Compound 1 (PGW) (10, 20mg/kg, oral), in the forced swim test (FST) on distance moved (Fig. 12A); on velocity (Fig. 12B); on strong mobility (Fig. 12C); and on immobility (Fig. 12D).
  • PGW Compound 1
  • Figs. 13A-C show the effect of Compound 1 (PGW-4) (10, 20, 30 mg/kg, oral) in the FST on immobility (Fig. 13A); on distance moved (Fig. 13B); and on strong mobility (Fig. 13C).
  • PGW-4 Compound 1
  • Figs. 14A-B show the effect of olanzapine in comparison to Compound 1 (PGW) in the FST on distance moved (Fig. 14A) and immobility (Fig. 14B).
  • PGW Compound 1
  • Figs. 15A-E show the effect of Compound 1 (PGW-4) and diazepam in the elevated plus maze test on mice frequency in-zone (Fig. 15A); on total duration in zone (Fig. 15B); on velocity (Fig. 15C); and rearing frequency (Fig. 15D).
  • Fig. 15E shows the effect of Compound 6 (PGW-5) in the elevated plus maze test.
  • Fig. 16 shows the effect of 10 and 20 mg/kg of Compound 1 (PGW-4), administered p.o. on latency to platform.
  • Fig. 17 shows the effect of acute treatment of Compound 1 at 10 and 20 mg/kg given p.o. on the spatial cognitive tasks in the Morris Water Maze in rats pretreated with MK-801.
  • Fig. 18 shows the effect of acute use of Compound 6 at 10 mg/kg given p.o. on the spatial cognitive tasks in the Morris Water Maze in rats pretreated with MK-801.
  • Fig. 19 shows the effect of Compound 1 on the mice body weight.
  • Fig. 20 shows the effect of treatments with different drugs on glioma viability.
  • the compounds of the invention may be prepared according to a variety of procedures, as disclosed and exemplified herein.
  • One general way to prepare the compounds of the general formula (A), substituted with the appropriate amino acid, e.g., glycinyl, serinyl or sarcosinyl moieties directly or through a linker, as shown in the specific structures herein, is to first prepare the demethylated derivatives of the parent CNS-active agents (e.g. des-Me-olanzapine, cfes-Me-clozapine).
  • the parent CNS-active agents e.g. des-Me-olanzapine, cfes-Me-clozapine.
  • These can be prepared by coupling two ⁇ rt/r ⁇ -disubstituted aromatics: one bearing a nitro group in an ortho position to a good leaving group (e.g., fluoride, chloride), while another is an ortho- cyano aromatic amine, phenol or thiophenol.
  • the coupling (for example through an aromatic nucleophilic substitution) forms a nitro cyano-diarylamine, nitro cyano- diarylether, or nitro cyano-diarylthioether.
  • the nitro group is reduced to amine with a simultaneous central diazepine ring closure.
  • the formed tricyclic amidine reacts with piperazine, forming the des-Me form of the L fragment of the target compound, as disclosed and exemplified herein.
  • the piperazine secondary amine of this intermediate can be further reacted with a ⁇ -iodo-alanine, or dehydroalanine derivative (where the linker moiety is absent) or with 0-iodoalkyl serine derivatives (where the linker moiety is present).
  • the amine of the aminoacid moiety may be protected utilizing any protecting groups known to the person skilled in the art. Typically, in the following examples, the amine was protected with the Boc-protecting group. Deprotection at the final step with an acid such as HCl, afforded the desired active compound in the trihydrochloride salt form.
  • the cooled reaction mixture was poured to 5% citric acid solution in H 2 O, extracted by DCM, and the separated organic layer was washed by brine, dried by MgSO 4 and evaporated.
  • the black oil residue (0.52g) of the intermediate dichloroacetyl derivative was dissolved in 3 ml dry DCM and DBU (0.33ml) in 2 ml DCM was added.
  • the reaction mixture was refluxed under N 2 overnight.
  • the cooled solution was poured to 5% citric acid aqueous solution, extracted by DCM, and the organic layer was washed by brine, dried by MgSO 4 and evaporated.
  • reaction mixture was then poured into a 1 M solution of sodium thiosulfate in H 2 O and extracted by EtOAc (three times with 20 ml). The combined organic layer was washed by brine and dried over MgSO 4 . The solvent was evaporated and the crude was purified by flash chromatography on silica gel (elution with isocratic 20% EtOAc/Hexanes) to give the pure M in 25% yield (0.093 g).
  • mice Male ICR or Balb/C mice, 6 to 8 weeks of age were used. All animals were housed (4-5/cage) under controlled conditions (temperature, light, humidity) given food and water ad libitum and allowed for 5-7 days of acclimatization before the beginning of experimentation.
  • Compound of the invention such as Compounds 1, 3 or 6, or olanzapine were administered orally to the mice at an equimolar dose and the behavioral tests were performed 1-4 hr later. The following tests were performed:
  • Climbing behavior being defined as the upward-directed movements (vertical) of the forepaws along the side of the swim chamber.
  • mice The test in mice was conducted acutely (60-90 minutes post oral drug administration) and animals were dropped to the cylinder for 6 minutes and scoring was performed in the last 4 minutes after 2 minutes of adaptation.
  • the procedure consists of subjecting an animal, usually a rodent, to an unknown large environment from which escape is prevented by surrounding walls.
  • the open field test is now one of the most popular procedures in animal psychology (Crawley, et al., Exploratory behavior models of anxiety in mice, Neurosci Biobehav Rev 9 (1985), pp. 37-44).
  • the procedure involves forced confrontation of a rodent with the situation.
  • the animal is placed in the center or close to the walls of the apparatus and the following behavioral items are recorded for a period ranging from 5 to 20 minutes: horizontal locomotion, and frequency of rearing or leaning.
  • rodents spontaneously prefer the periphery of the apparatus to activity in the central parts of the open field.
  • Increase in time spent in the central part as well as of the ratio central/total locomotion or decrease of the latency to enter the central part are indications of anxiolysis.
  • the amphetamine-induced hyperactivity and motility is one of the most popular animal models for schizophrenia (Pouzet B, et al, Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav Apr; 71(4):655-665, 2002 and Geyer, et al., Animal behavior models of the mechanisms underlying antipsychotic atypicalicity, Progress in Neuro-Psychopharmacol & Biological Psychiatiy, 27, 1071-79, 2003).
  • Amphetamines are known to augment dopaminergic and noradrenergic neurotransmission by inducing catecholamine release and preventing catecholamine reuptake
  • mice placed in individual barrels.
  • Olanzapine, or Compound 1 for example at a dose of 10 and 20mg/kg
  • mice were administered interperitoneal' (i.p.) to the mice 0.5 hour prior to subcutaneous (s.c.) administration of amphetamine (3mg/kg).
  • amphetamine 3mg/kg
  • the locomotor activity, number of rearings and head movements was recorded every 15 minutes for 2 h.
  • MK-801 is an analogue of PCP which inhibits NMDA receptors and elicits hyperlocomotion and stereotypic behavior in rodents and is used as an animal model of schizophrenia (Stephen, et al., Topiramate antagonizes MK-801 in an animal model of schizophrenia, Eur. J. Pharmacol. 449, 2002, 121-5).
  • MK-801 (0.15mg/kg i.p) was administered 40 minutes after Compound 1 (or any one of the other compounds of the invention) or a vehicle, and 20 minutes prior to placing the mouse in an open field.
  • MK-801 inhibits NMDA receptors and elicits hyperlocomotion. Therefore, where an antagonism of the hyperactivity-induced by the MK-801 is observed upon administration of a compound of the invention, it is an indication as to the positive modulation of the NMDA activity. In other words, such a compound may be considered as useful in the treatment of schizophrenia.
  • Catalepsy in mice and rats serves as a behavioral model for the manifestation of the extrapyramidal adverse effects of neuroleptics (Worm, et al., Dopamine-like activities of an aminopyridazine derivative, CM 30366. A behavioral study, Naunyn- Schmeideberg's Arch Pharmacol, 334, 246-52, 1986).
  • the elevated plus maze is a widely used method to test anxiety in rodents (Pellow, et al., Pharmacol. Biochem. Behav., 24, 525-529 (1986)).
  • the apparatus was made of wood and painted black, with two opposing open arms and two opposite enclosed arms of the same size. The arms were attached to a central square shaped in a plus sign. The whole apparatus was placed 50 cm above the floor. Anxious animals refrain from entering the open arm and prefer the closed arm.
  • Benzodiazepines were shown to increase the time spent in the open arms and the frequency of entries to the open arms (Pellow, et al., Validation of openxlosed arm entries in an elevated plus- maze as a measure of anxiety in the rat, J. Neurosci. Methods, 14, 149-167 (1985)).
  • mice were administered orally with 10 and 20 mg/kg of Compound 1 or Compound 6 and with a vehicle or with diazepam (lmg/kg) administered per os (p.o.) 90 minutes before they were placed in the center of the maze.
  • the frequency to the open arms, the time spent in the different arms, the velocity and number of rearings of the animals in each zone were recorded (Noldus).
  • Mice treated with a compound of the invention and exhibit preference of entering to the open arms, or the center, and demonstrate a decrease in the time spent in the closed arms, are indicative of anxiolytic activity imposed by the compound.
  • the Morris Water Maze is a well known test aimed to assess spatial cognitive tasks (Anger, et al., Animal test systems to study behavioral dysfunctions of neurodegenerative disorders, Neurotoxicology, 12, 403-13 (1991)).
  • the maze consists of a circular pool measuring 1.80 m in diameter 60 cm in height. The pool was filled with water (21 ⁇ 1°C) to a depth of 30 cm. A circular hidden escape platform (10 cm in diameter) was placed just below the water surface.
  • the test room contained several permanent extra maze cues such as the rat housing rack, laboratory table, posters on the walls, etc.
  • mice The effect of Compound 1 on the behavior of mice in the open field and the dose-dependent effect following i.p administration were evaluated.
  • Na ⁇ ve male Mice (Balb/c, Harlan Israel) were used.
  • Mice were monitored for lhr (every 5 minutes) using the Noldus system, and their distance moved, velocity, time of immobility and number of rearings was recorded.
  • Figs. IA-D indicate, Compound 1 induced a dose dependent decrease in the horizontal and vertical motility of the mice. At 12.5 mg/kg the drug did not modify significantly neither parameter and tended to increase rearing frequency. Moreover, doses up to 50mg/kg induced a mild inhibition of the horizontal and the vertical motility. Higher doses showed a marked sedative effect and motility was reduced to minimum.
  • mice in the open field were also examined.
  • Na ⁇ ve male mice (Balb/c, Harlan Israel) were used. Animals (6 per group) were administered with Compound 6 (12.5, 25 and 50 mg/kg, i.p.) lhr prior to placing each in the open field. Mice were followed for lhr (every 5 minutes) using the Noldus system, and their distance moved, velocity, time of immobility and number of rearings was recorded.
  • Figs. 2A-D show, Compound 6 induced a dose dependent decrease in the motility of the mice expressed by decreased distance moved and velocity. The effect was mild up to 50mg/kg. Compound 6 induced inhibition of the horizontal (distance) and the vertical motility (number of rearings). The drug increased the duration of "not moving" periods at all doses. It can thus be concluded that Compound 6 as is the case with Compound 1 has a mild sedative effect, as reflected by decreasing horizontal and vertical activity, mainly due to increased periods of immobility. The effect of Compound 6 on the distance moved in Balb/c mice exposed to MK-801 (15mg/kg) i.p.
  • mice Na ⁇ ve male mice (Balb/c, Harlan Israel) were used. Animals were administered with Compound 3 (12.5, 25 and 50 mg/kg, i.p., 6 per group) lhr prior to placing each in the open field. Mice were followed for lhr (every 5 minutes) using the Noldus system, and their distance moved, velocity, time of immobility and number of rearings was recorded.
  • Figs. 4A-C show the behavioral parameters of Compound 3 in the open field.
  • Compound 3 induced a mild decrease in the motility of the mice expressed by decreased distance moved and velocity up to 25mg/kg and a marked decrease in the motility parameters at 50mg/kg (Fig. 4A).
  • the drag dose dependently increased the duration of "not moving" periods (Fig. 4B) and decreased the number of rearings vs. controls (Fig. 4C).
  • the amphetamine— induced hyperactivity and motility is one of the most popular animal models for schizophrenia.
  • the experiment was conducted with ICR male mice placed in individual barrels. Compound 1 (20mg/kg) was administered p.o to the mice lhr prior to i.p. administration of amphetamine (2.mg/kg).
  • the hyperactive behavior expressed by the number of climbings and rearings and the stereotypic behavior expressed by the number of head movements was recorded every 15 minutes over a period of Ih.
  • Fig. 7A shows the effect of Compound 3 (12.5, 25 and 50mg/kg. i.p at -60 minutes) on distance moved. Results demonstrate a dose-dependent decrease in the distance moved with normalization at 12.5mg/kg and a marked decrease at higher doses.
  • Fig. 7B shows the immobility time of amphetamine and amphetamine combined with Compound 3. The results show that amphetamine was similar to controls yet Compound 3 already at 12.5mg/kg antagonized the hyperactivity ensued by the amphetamine.
  • MK-801 an NMDA receptor antagonist
  • NMDA receptor antagonist an NMDA receptor antagonist
  • the experiment was conducted with Balb/c male mice (Harlan II), 6 per group.
  • Compound 1 50mg/kg was administered i.p. (lhr before experimentation), to mice alone or combined with MK-801 (0.15mg/kg, i.p.) administered 20 minutes prior to placing the mice individually in an open field for 60 minutes.
  • the hyper- active behavior expressed by hyperlocomotion, velocity, strong mobility, number of rearing was evaluated using the Noldus system, each point represents the mean+/- 6 determinations.
  • FIGs 8A-E show, at 50mg/kg Compound 1 induces a clear cut decrease in both basal and MK-801 -induced stimulation of horizontal motility as expressed by distance moved, velocity, strong mobility (which is expressed by moving the center of gravidance by more than 30%). Compound 1 also markedly suppressed vertical motility (number of rearings) alone and increased the inhibition of rearings presented by MK-801 as compared to controls. This suggests that Compound 1 has a significant positive modulation effect on the NMDA glutamate receptor. As Figs. 9A-B show, Compound 1 at 30 and 50mg/kg, i.p. inhibited in a dose related manner the hyperlocomotion effect of MK-801. Figs.
  • Figs. 10A-D shows the effect of Compound 3 (12.5, 25 and 50 mg/kg, i.p.) on hyperactivity-induced by MK-801 (0.15mg/kg, i.p.) in Balb/c mice.
  • the data shows that Compound 3 induced a dose dependent decrease in MK-801 -induced hyperactivity, a slight effect was observed with 7.5mg/kg, normalization of activity was achieved with 25mg/kg and sedation with 50mg/kg (Fig. 10A). Immobility was not found with the small and intermediate doses (25mg/kg) and appeared with the high dose (Fig. 10B).
  • Compound 3 at the low dose tended to increase the frequency to the center of the field (Fig. 10C) and the time spent in the center (Fig. 10D).
  • Figs. 14A-B Males ICR mice were used. Animals were administered orally with olanzapine or Compound 1 (20 mg/kg) or with a vehicle. The results shown in Figs. 14A-B indicate that orally administered olanzapine at 20mg/kg significantly decreased distance moved, velocity and strong mobility (climbing) and increased immobility. Compound 1 at the same dose did not modify velocity and distance moved, and significantly decreased strong mobility (climbing) and immobility compared to vehicle and to olanzapine in treated animals. These data suggest that Compound 1 is different from olanzapine, and at 20 mg/kg it causes decrease in immobility, suggesting a potential antidepressant activity.
  • Fig. 15A shows the effect of Compound 1 on frequency of the mice to the different arms. The results show that mice treated with Compound 1 (20mg/kg) frequented significantly more the open arm and the center resembling the mice treated with diazepam at lmg/kg.
  • Fig. 15B shows the effect of Compound 1 on duration of time spent in the different zones of the elevated plus maze. At 20mg/kg Compound 1 increased the time spent in the center, but did not significantly affect the time spent in the closed and the open arm at variance from diazepam.
  • Fig. 15C shows the velocity of the mice which was higher in the mice treated with diazepam but not in the mice treated with Compound 1.
  • Fig. 15D shows the frequency of rearings of mice treated with Compound 1, diazepam or controls. The results show increased number of rearings in the open arm in the diazepam and the Compound 1 treated groups. As may be noted, diazepam significantly increased the number of rearings also in the center.
  • Compound 1 showed anxiolytic activity which resembles diazepam, but differs from it in its intensity and in the effects on velocity.
  • Fig. 15E shows the total time spent by the mice administered with Compound 6 (3, 9 and 27 mg/kg, orally) on the different arms of the maze. The results demonstrate that mice treated with Compound 6 spent more time on the open arms and less on the center, suggesting a potential anxiolytic activity for the Compound.
  • the Morris Water Maze is a well known test aimed to assess spatial cognitive tasks.
  • the maze consists of a circular pool measuring 1.80 m in diameter 60 cm in height.
  • the pool was filled with water (21 ⁇ 1°C) to a depth of 30 cm.
  • a circular hidden escape platform (10 cm in diameter) was placed just below the water surface.
  • the test room contained several permanent extra maze cues such as the rat housing rack, laboratory table, posters on the walls, etc.
  • rats were given Compound 1 orally on day 1 and the first test begun 90 minute later, six trials per day, for 3 consecutive days, to find the hidden platform (acquisition phase).
  • the escape latency i.e., the time required by the rat to find and climb onto the platform, was recorded for up to 120 sec.
  • Each rat was allowed to remain on the platform for 30 sec, after which it was removed to its home cage. If the rat did not find the platform within 120 sec, it was manually placed on it and returned to its home cage after 30 sec.
  • a video camera was placed above the center of the pool for tracking the rat, and a video tracking system (Noldus) with online digital output directly fed data into a computer. Data were analyzed using Etho Vision automated tracking system software (Noldus).
  • Fig. 16 shows the effect of 10 and 20 mg/kg of Compound 1, administered po, on latency to platform.
  • Compound 1 at 20mg/kg showed a faster learning on the first day of the spatial task and reached the platform earlier. Also on the second day, an improvement was noticed of task execution by mice treated with Compound 1 (20mg/kg). On the third day, no difference was found between all groups, and all rats reached rapidly the platform.
  • Fig. 17 shows the effect of acute use of Compound 1 at 10 and 20 mg/kg given p.o. on day 1 on the spatial cognitive tasks in the Morris Water Maze in rats pretreated (-30 minutes) with MK-801 (on day 1) at 0.15 mg/kg, i.p. MK-801 alone induced a significant impairment in the memory tasks of the rats as expressed by increased latency to the platform as compared to the normal controls.
  • Compound 1 at both doses decreased the latency to the platform on day 3 of the experiment but not on days 1 and 2.
  • Fig. 18 shows the effect of acute use of Compound 6 at 10 mg/kg given p.o. once on day 1 on the spatial cognitive tasks in the Morris Water Maze in rats pretreated (-30 minutes) with MK-801 (0.15 mg/kg, i.p.). MK-801 alone induced a significant impairment in the memory tasks of the rats as expressed by increased latency to the platform as compared to the normal controls. Compound 6 at 10 mg/kg decreased the latency to the platform on days 2 and 3 of the experimentation. In similarity with Compound I 5 the described use of Compound 6 suggests use in relieving some of the cognitive impairments seen in states of schizophrenia due to decreased NMDA activity.
  • mice Male Balb/c mice were used. Animals were transferred to the behavior room 24hr before the experiment. Compound 6 (3, 9, or 27 mg/kg) or vehicle were adrninistered orally 90 minutes before testing. Each treatment group included 5 animals. The effect of Compound 6 on duration of time spent in the different zones of the elevated plus maze is evident from the dose-dependently increase in the time spent in the open arms and decrease in the time spent in the center. The drug did not significantly affect the time spent in the closed arm. This suggests that Compound 6 has an anxiolytic activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention discloses central nervous system (CNS) active compounds, such as psychotropic agents, having anti-dopaminergic activity and ability to modulate glutamate N-menthyl-D-aspartate (NMDA) receptor activity. Such agents are useful in the treatment of schizophrenia and bipolar depression, and in particular have the ability to alter the negative symptoms of schizophrenia. Such agents are also useful in altering states of other mood disorders such as depression and anxiety, cognitive deficits, movement disorders and drug addiction.

Description

NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA
ACTIVITY
FIELD OF THE INVENTION
The present invention is generally in the field of pharmaceutical compositions and methods for the treatment of psychological and/or psychiatric diseases or disorders.
BACKGROUND OF THE INVENTION
Glutamate is the most abundant excitatory amino acids in the central nervous system (CNS). Glutamate acts through a number of receptors that affect both fast and slow neurotransmission. The fast ionotropic N-methyl-D-aspartate (NMDA), the amino- 3-hydroxy-5-rnethyl-4-isoxazole (AMPA), and the slow metabotropic kainate receptor are a series of G-protein coupled receptors. The ionotropic NMDA receptors are excitatory which has binding sites for glutamate and glycine, and possess an important role in memory and in mood disorders. The metabotropic kainate glutamate receptors (mGluRs) are present at both presynaptic and postsynaptic sites and are considered major targets in the area of neuropharmacology, including schizophrenia, depression, learning, memory, anxiety, seizures, addiction to drugs, neurodegeneration and developmental regulation of synaptic circuits.
The anti-psychotic drugs are widely used in the treatment of central nervous system (CNS) psychotic , diseases and disorders, such as schizophrenia. These agents block generally dopamine receptors and are divided into typical and atypical classes; phenothiazines are, for example, typical antipsychotics and clozapine, olanzapine and risperidone are classified as atypical antipsychotics. It is well known in the art that typical neuroleptic agents induce extrapyramidal symptoms, which include rigidity, tremor, bradykinesia (slow movement), and bradyphrenia (slow thought), as well as tardive dyskinesia, acute dystonic reactions and akathasia. Atypical antipsychotics cause minimal extrapyramidal symptoms and thus rarely cause tardive dyskinesias, akathasia or acute dystonic reactions. The administration of atypical antipsychotic agents involves other side effects such as increase of body weight, mood disturbances, sexual disfunction, sedation, orthostatic hypotension, hypersalivation, lowered seizure threshold and, in particular, agranulocytosis. Schizophrenia is a chronic, debilitating disease with significant morbidity and mortality that often requires antipsychotic pharmacotherapy for life. Current therapy consists of neuroleptics of the typical and the atypical type which share a common anti- dopaminergic activity. In recent years, evidence has been accumulated suggesting that schizophrenia and bipolar disorders are also associated with disturbance in GABA and glutamate transmission in the brain. Recent studies suggest that schizophrenia is associated with NMDA receptor pathology. This hypothesis is based on the experimental finding that agents that block NMDA receptors such as phencyclidine (PCP) and MK-801 induce psychoses similar to that associated with schizophrenia. Post-mortem data in brains of schizophrenic patients showed also a decrease in the expression of several glutamate receptor subtypes including NMDA, AMPA and Kainate in different brain areas. Since hypo function of the NMDA system is considered to have an important role in schizophrenia, and schizophreniform psychosis caused by PCP resembles schizophrenia especially in negative symptoms and cognitive dysfunction, it was suggested that NMDA inhibition would lead to diminished GABAergic tone, which in turn will induce disinhibition of glutamatergic AMPA receptor resulting in excitotoxic neuronal damage and psychosis.
Since direct-acting NMDA agonists, such as glutamate, might be neurotoxic, research focused on assessing the therapeutic activity of partial or full agonists on the glycine (GLY) site of the NMDA receptors. Agents like D-serine and D-cycloserine (DCS) showed in some clinical studies an improvement of mainly primary negative symptoms of schizophrenia when used as adjuvants to conventional neuroleptics such as risperidone and olanzapine. Sarcosine is a glycine transporter 1 inhibitor found efficacious in improving symptoms (negative and positive) of patients with stable chronic schizophrenia. The disadvantage, however, associated in the use of these amino acids lies in the fact that they scarcely penetrate the blood brain barrier (BBB).
Glutamate receptors subtype antagonists, agonists and partial agonists are target of intensive research. The NMDA receptor antagonist memantine was developed for the treatment of Alzheimer's disease. The partial agonist agent D-cycloserine was found to induce some antidepressant and anxiolytic activity in animal models and to improve mood, insomnia and appetite. It is suggested that its anxiolytic effect is related to increased learning and fear extinction. Yet, a significant antidepressant activity of D- cycloserine compared to placebo in men was not observed. Furthermore, agents targeting both the ionotrophic and the metabotrophic receptors of glutamate are under different stages of development for the treatment of anxiety, depression, cognitive and motor disorders.
SUMMARY OF THE INVENTION
The present invention discloses novel Central Nervous System (CNS) active compounds, such as psychotropic agents, having anti-dopaminergic activity and ability to modulate glutamate N-methyl-D-aspartate (NMDA) receptor activity. Such agents are useful in the treatment of schizophrenia and bipolar depression, and in particular have the ability to alter the negative symptoms of schizophrenia. Such novel agents are also useful in altering states of other mood disorders such as depression and anxiety, cognitive deficits, movement disorders and drug addiction.
In one aspect of the present invention, there is provided a CNS active compound (herein a compound of the invention) conjugated to a modulator of the glutamate NMDA receptor. The CNS compound conjugated as recited herein, as known to a person skilled in the art, is a therapeutic agent that acts at a site within the central nervous system, particularly within the brain. CNS-active compounds include CNS depressants, CNS stimulants, and drugs that selectively modify CNS function, such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, anti-emetics, analgesic-antipyretics, certain stimulants, antidepressants, antimanic agents, antipsychotic agents, sedatives and hypnotics.
Within the scope of the present invention, the CNS-active agents are not limited to agents that act solely within the central nervous system.
In one embodiment, the compound of the invention, or a salt, a prodrug, or a stereoisomer thereof, is of the general formula L-M-V, wherein L is a CNS active moiety; M is a linker; and V is a modulator of the glutamate NMDA receptor.
It should be noted that within the scope of the present invention, the CNS active agent when part of a compound of the invention is referred to as a "CNS active moiety", signifying its conjugation to the linker, M, or the modulator of the glutamate NMDA receptor V. - A -
The compound of the formula L-M-V may be schematically exemplified as shown:
Figure imgf000005_0001
Linker M may be conjugated to the CNS active moiety, L, via any atom of the CNS active moiety. The conjugation to L may be through one or more of the native atoms of the CNS active compound, namely through one or more atoms selected, for example, amongst C, N, S, P, and O, of the CNS active compound (in its unconjugated form), or through a chemically modified part of the CNS active compound, provided that such a modification (necessary for the attachment of the linker M) does not alter or diminish the activity associated with the CNS active compound.
Linker M may be conjugated to the modulator of the glutamate NMDA receptor, V, through any atom of the linker. As the modulator is typically an amino acid or an amino acid derivative, conjugation to the amino acid or amino acid derivative is typically through the α-carbon atom of the amino acid or amino acid derivative, as demonstrated below.
In cases where chemical modification of the CNS active compound and/or the modulator is required to enable bonding of the linker moiety, M, thereto (to either or both L and V), the modification may be any such modification known to a person skilled in the art. Based on the description provided herein, the artisan would know how to chemically modify a CNS active compound for conjugation. For general synthetic methodologies, see for example Comprehensive Organic Transformations: A Guide to Functional Group Preparations, Richard C. Larock, 2n Ed., John Wiley & Sons, Inc., 1999.
In some embodiments, the bond between M and L and/or between M and V is non-hydrolysable, namely the linker M does not dissociate from either the CNS active moiety and/or the modulator of the glutamate NMDA receptor, V5 under aqueous physiological conditions, hi some embodiments, the bonds between M and L and/or M and V are covalent. In some embodiments, only one of the bonds between M and L or M and V is a non-hydrolizable bond while the other is a hydrolizable bond.
In other embodiments, both the bonds between M and L and between M and V are non-hydrolizable.
As stated above, the CNS active moiety may be any one moiety derived from a CNS active compound selected from the classes typically referred to as CNS depressants, CNS stimulants, and drugs that selectively modify CNS function, such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, antiemetics, analgesic-antipyretics, stimulants, "antidepressants, antimanic , agents, antianxiety agents, antipsychotic agents, sedatives and hypnotics.
In some embodiments, the CNS active moiety is selected from an anti-depressant compound, an anti-psychotic compound, an anti-epileptic compound, anti-anxiety and a compound for treating a movement disorder.
In one embodiment, the CNS active moiety is derived from an anti-depressant compound selected amongst anti-unipolar agents and anti-bipolar agents. Non-limiting examples of anti-unipolar agents are fluoxetine, fluvoxamine, desipramine, paroxetine and sertraline.
Non-limiting examples of anti-bipolar agents are remoxipride, alizapride, clozapine, olanzapine and quetiapine.
In another embodiment, the CNS active moiety is derived from an anti-psychotic compound selected from clozapine, olanzapine, quetiapine, loxapine, risperidone, flupenthixol, thioridazine, chlorpromazine, perphenazine, fluphenazine, zuclopenthixol, spiperone, amisulpride, sulpiride, remoxipride and alizapride.
In yet another embodiment, the CNS active moiety is derived from an antianxiety compound selected from fluoxetine, fluvoxamine, desipramine, paroxetine and sertraline.
In some other embodiments, the CNS active moiety is derived from a CNS active compound selected amongst monocyclic, bicyclic and tricyclic anti-psychotic agents.
Non-limiting examples of monocyclic agents are amisulpride, sulpiride. Non- limiting examples of bicyclic agents are spiperone, remoxipride, alizapride. Non- limiting examples of tricyclic agents are chlorpromazine, perphenazine, fluphenazine, zuclopenthixol, clozapine, olanzapine, quetiapine, loxapine, flupenthixol and thioridazine.
In certain embodiments, the CNS active moiety is derived from clozapine, olanzapine, or quetiapine.
Within the scope of the present invention, the expression "CNS active moiety derived from" signifies the conjugation of a CNS active compound, as defined and exemplified, to afford a conjugate form of the compound, namely a conjugate moiety having the linker conjugated thereto. For example, a CNS active moiety derived from clozapine is a compound of the invention in which L is clozapine, M is a linker conjugated to clozapine, and V is a modulator conjugated to M.
The linker M may or may not be present.
In some embodiments, where M is absent, L is conjugated directly to V.
In other embodiments, M is present and is typically a linear group conjugating L and Y through one or more atoms on each moiety. The linear group is typically a chain of between 1 and 8 atoms having at least one atom selected from C, N, O and S.
In some embodiments, M is selected from -NH-, -NH2 +-, -O-, -S-, C1-C8- alkylene, C3-C8-cycloalkylene, -CH2-O-CH2, -(CH2)n-O-(CH2)n-, -(CH2-O)n-, and -(CH2CH2-O)n-, wherein said alkylene and cycloalkylene may optionally be substituted by one or more groups selected from C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl, and wherein each of n, independently of each other, is an integer between zero and 3 (i.e., being 0, or 1, or 2, or 3). The alkylene or cycloalkylene may be interrupted by at least one heteroatom selected from N, O and S or by at least one or more double or triple bond.
Non-limiting examples of a linker are -NH-, -O-, -S-, methylene, ethylene, propoylene, isopropylene, isobutylene, sec-butylene, tert-butylene, butylenes, pentylene, isohexylene, hexylene, heptylene, octylene, -(CH2-CH=CH-CH2)-, -(CH=CH2-CH2- CH2)-, -(CH2-CH=CH-CH2-CH2-CH2)-, -(CH2-C≡C-CH2)-, -(C≡C-CH2-CH2)-, -(CH2- NH-CH=CH-CH2)-, -(CH2-NH-CH2-CH2-CH2)-, -(CH2-O-CH2-CH2)-, -(CHj)n-O- (CH2V, -CH2-O-CH2, -(CH2-O)n-, -(CH2CH2-O)n- wherein n is an integer between O and 3, and substituted derivatives thereof.
The modulator of the glutamate NMDA receptor, V, is typically an amino acid, or ester, or amide, or alkylated amine of said amino acid. In some embodiments, the amino acids are selected from glycinyl (derived from glycine), sarcosinyl (derived from sarcosine), serinyl (derived from serine) and cysteinyl (derived from cysteine). In other embodiments, the amino acids are esters or amides of glycinyl, sarcosinyl, serinyl and cysteinyl.
In further embodiments, the modulator of the glutamate NMDA receptor is (lS,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) or a derivative thereof.
Non-limiting examples of esters of the above amino acids are C1-C6 esters such as methyl, ethyl, propyl, butyl and hexyl esters of glycinyl, sarcosinyl, and serinyl. The amides may be of C2-C6 acids (of the general formula C1-C6-COOH5 wherein the C1-C6 carbon moiety attached to the -COOH, from which the amide is derived, is an alkyl having between 1 and 6 carbon atoms).
It is to be understood that the compounds provided herein may contain one or more chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures. In the case of the amino acid moieties constituting the functional moieties of the glutamate NMDA receptor, either the L- or D-form may be present. As used herein, the term "amino acid" refers to α-amino acids which are racemic, or of either the D- or L-configuration.
It is also to be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo. As such, one of skilled in the art will recognize that administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form.
The term "alkylene" as used herein refers to an alkyldiyl functional group having two free valences carbon atoms, namely an alkyl group substituted at both ends. The expression "Ci-Cg alkylene" refers to such an alkyl group having between 1 and 8 carbon atoms. The term "cycloalkylene" similarly refers to a cyclic alkyl being substituted at both ends.
Additionally, as may be known to a person skilled in the art, the term "Cj-C V alkyl" refers to an aliphatic chain of between 1 and 4 carbon atoms, being substituted at one position only. The term "C2-C4 alhenyl" refers to a carbon chain having between 2 and 4 carbon atoms and at least one C-C bond being a double bond. The term "C2-C4 alkynyl" refers to a carbon chain having between 2 and 4 carbon atoms and at least one C-C triple bond.
In certain embodiments of the invention, the CNS active compound is a tricyclic anti-psychotic agent of the general formula (A) and the CNS active moiety is derived thereform:
Figure imgf000009_0001
Formula (A) wherein
X is selected from -NH-, -O- and -S-;
Y is selected from -C=C-, -NH-, -O-, and -S-;
Z and Z' are each independently selected from C1-C4 alkyl and halide (I, Br, Cl and F). In some cases, each of the rings substituted by Z or Z' may he substituted by one or more of Z and/or Z1.
In some embodiments, X is -NH- or S and Y is -C=C- or S. In other embodiments, where X is -NH-, Y is -C=C- or -S-. In other embodiments, where X is S5 Y iS -C=C-.
In further embodiments, Z is a methyl group. In still further embodiments, Z' is a halide.
In further embodiments, the tricyclic compound of formula (A) is selected from olanzapine, quetiapine, and clozapine, the structures of which are shown below and the CNS active moiety is derived from olanzapine, quetiapine, or clozapine:
Figure imgf000010_0001
Olanzapine Clozapine
Figure imgf000010_0002
Quetiapine
These compounds may be conjugated to a linker through any one of their carbon or heteroatoms (i.e., S, N or O). As an example, olanzapine may be conjugated to a linker via any of the atoms shown with an arrow:
Figure imgf000010_0003
Olanzapine In some embodiments, where the CNS active moiety is derived from olanzapine, the compound of the general formula L-M-V is a compound of formula (I):
Figure imgf000011_0001
Formula (I)
wherein M and V are as defined above.
In some embodiments, the modulator of the glutamate NMDA receptor, V, is glycinyl, or an ester thereof, and the compound is of the formula (Ia):
Figure imgf000011_0002
Formula (Ia)
wherein in the compound of general formula (Ia):
M is selected from null, -NH-, -0-, -S-, Ci-C8-alkyl, C3-C8-cycloalkyl, -CH2-O- CH2-, -(CH2-O)n-, and -(CH2CH2-O)n-, n is an integer between 0 and 3, and R is selected from H and a C1-C4 alkyl.
In some embodiments of formula (Ia), the linker is absent and exemplary compounds of the invention are herein designated Compounds 1 and Compound 2.
Figure imgf000012_0001
Compound 1
Figure imgf000012_0002
Compound 2
In some other embodiments of formula (Ia), the linker contains at least one heteroatom selected from N, O and S.
In some embodiments, the linker is a Ci-C5-alkylene containing at least one heteroatom. In some further embodiments, the Q-Cs-alkylene is interrupted by an O atom and exemplary groups are -CH2-O-CH2, -(CH2-O)n-, and -(CH2CH2-O)n-, wherein n is an integer between 1 and 3 (i.e., 1 or 2 or 3).
Exemplary compounds of such a structure of formula (Ia) are the compounds herein designated as Compound 3 and Compound 4.
Figure imgf000013_0001
Compound 3
Figure imgf000013_0002
Compound 4
In certain embodiments of general formula (I), the modulator of the glutamate NMDA receptor is sarcosinyl, or an ester thereof or serinyl, or an ester thereof, and the compound is of formula (Ib):
Figure imgf000014_0001
Formula (Ib)
wherein in the compound of formula (Ib):
M is selected from null, -NH-, -0-, -S-, Ci-Cg-alkyl, C3-C8-cycloalkyl, -CH2-O- CH2-, -(CH2-O)n-, and -(CH2CH2-O)n-, n is an integer between O and 3,
R and R', independently of each other are selected from H and a d-Gt-alkyl, and R" is selected from H and -CH2OH.
In some embodiments, where R' is a Ci-C4-alkyl, R" is H and R is optionally different from H.
In some embodiments, where R' is H, R" is -CH2OH.
In other embodiments, in the compound of formula (Ib), the linker M is absent, R" is H and R' is selected from H and C1-C4-alkyl. Exemplary compounds of the invention are herein designated Compound 5 through Compound 10.
Figure imgf000015_0001
Compound 5
Figure imgf000015_0002
Compound 6
Figure imgf000015_0003
Compound 7
Figure imgf000015_0004
Compound 8
Compound 9
Figure imgf000016_0002
Compound 10
In other embodiments of formula (Ib), the linker, M, is Q-Cs-alkylene containing a heteroatom selected from N, O and S.
In some embodiments, the linker is a Q-Cs-alkylene interrupted by at least one O atom, such as -CH2-O-CH2, -(CH2-O)n-, and -(CH2CH2-O)n-, wherein n is as defined above. Exemplary compounds are herein designated as Compound 11 through Compound 13.
Figure imgf000017_0001
Compound 12
Figure imgf000017_0002
Compound 13
Similarly to Compounds 1 through 13, which, are based on olanzapine as the CNS active moiety, compounds of the general formula L-M-V which are based on clozapine and quetiapine have also been prepared. Table 1 lists an exemplary selection of compounds according to the invention. In Table 1, "Ola" stands for olanzapine; "CIo" stands for clozapine; and "Que" stands for quetiapine, each with a point of substitution as shown:
Figure imgf000018_0001
Olanzapine Clozapine
Figure imgf000018_0002
Quetiapine
Figure imgf000018_0003
Figure imgf000019_0001
Figure imgf000020_0001
Table 1: Compounds of the general formula L-M-V
The present invention thus also provides any one of Compounds 1 through 54 listed in Table 1, a salt thereof, a prodrug thereof, and a stereoisomer thereof.
The present invention further encompasses active compounds which are based on mono- and bicyclic antipsychotic agents such amisulpride, sulpiride, spiperone, remoxipride, and alizapride. Such compounds may be utilized as the CNS active moiety, L5 in the general formula L-M-V.
For example, the monocyclic anti-psychotic agent amisulpride may be conjugated to a linker at any one of the positions (others are also possible) shown with an arrow:
Figure imgf000021_0001
Amisulpride
Similarly, alizapride, a bicyclic anti-psychotic, may be modified at the shown positions:
Figure imgf000021_0002
Alizapride
The compounds of the invention may be prepared following total synthesis from commercially available starting materials or intermediates. As demonstrated below, olanzapine derivatives were prepared step-wise from substituted thiophene. The synthesis of clozapine proceeded step-wise from a substituted benzene. Once the backbone of the active moiety was prepared, substitution with an appropriate group, constituting the linker and/or the modulator of the glutamate NMDA receptor, was possible. The quetiapine derivatives were prepared via total-synthesis or alternatively via direct alkylation of the free hydroxyl group of the quetiapine skeleton.
Thus, in another aspect of the present invention, there is provided a method for the preparation of a compound of general formula L-M-V, said method comprising:
(a) providing a reactive precursor of a CNS active moiety, L;
(b) reacting said precursor under appropriate conditions with
(i) a derivative of a linker, M, and/or
(ii) a derivative of a the modulator of the glutamate NMDA receptor,
V, or (iii) a pre-synthesized product of a linker and a modulator of the glutamate NMDA receptor having the formula -M-V; whereby under the reaction conditions said reactive precursor of a CNS active moiety reacts with one of (i)-(iii) to afford, respectively,
(1) a CNS active moiety substituted with a linker, M, i.e., having the general formula L-M; or
(2) a CNS active moiety substituted with a modulator of the glutamate NMDA receptor modulator, V, i.e., having the general formula L-V (M being absent); or a CNS active moiety substituted with -M-V (in case steps (i) and (ii) are sequentially followed); or
(3) a CNS active moiety substituted with a modulator of the glutamate NMDA receptor modulator, V, through a linker, M, i.e., having the general formula L-M-V.
Where the intermediate is a precursor of L-M-V, being, for example, of the general structure L-M, the intermediate may be further reacted with an appropriate precursor of the modulator of the glutamate NMDA receptor to afford a compound of the general structure L-M-V.
The reactive precursor of a CNS active moiety, L5 is a precursor of the CNS active moiety which may be modified, by methods known in the art, to afford a CNS active moiety conjugated to a linker. The precursor may be one having a free amine group, an alcohol, a thiol, an aldehyde, a ketone, a carboxylic acid or an active carbon group, through which conjugation may take place. The conjugation of the moiety to the linker may take place, depending on the specific reaction conditions employed, under such experimental conditions as would be known to a person skilled in the art, to afford one or more of the following: high yield, selectivity, preference to a single isomer, etc.
The synthesis of specific isomers can be carried out employing methods within the knowledge of one skilled in the art, for example, stereochemically controlled synthesis using chiral synthons or chiral reagents.
The compounds of the invention typically contain at least one basic atom or substituent, and thus are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals (human and non-human), it is often desirable in practice to initially isolate the base compounds from the reaction mixture as other non- acceptable salts, such as perchlorates, picolinates, picrates, or the like, and then convert them to the free base compound by treatment with an alkaline reagent, as known to a person skilled in the art. Subsequently, the free base forms may be converted to the pharmaceutically acceptable acid addition salts.
The acid addition salts of the compounds of this invention are readily prepared by treating the compounds with equivalent amounts of a chosen mineral or organic acid in an aqueous solvent or in a suitable organic solvent, such as methanol or ethanol. The desired solid salt may then be readily obtained by, e.g., evaporation of the solvent.
The pharmaceutically acceptable acid forms of the compounds of the invention, are obtained from non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bi-tartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, andp-toluenesulfonate.
Certain compounds of the present invention have at least one acidic group and are thus capable of forming base salts with various pharmaceutically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and, particularly, the sodium and potassium salts.
The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of compounds of the present invention are those which form nontoxic base salts with the herein described acidic derivatives. These particular non-toxic base salts include those derived form such pharmaceutically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the compounds of the invention having at least one acidic group with an aqueous solution containing the desired pharmaceutically acceptable cation, and then evaporating the resulting solution to dryness, in some embodiments under reduced pressure. Typically, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum production of yields of the desired final product.
Compounds of the invention having both acidic and basic groups may also be obtained as internal salts (Z witter ions).
The present invention also relates to prodrug derivatives of the compounds of the invention. As known to the person skilled in the art, the term "prodrug" refers to pharmacologically inactive precursors of a drug that may be converted into its therapeutically active form under physiological conditions in vivo, for example, when they undergo solvolysis, or enzymatic degradation in blood, or in cells, (See as background reference: The Organic Chemistry of Drug Design and Drug Action, Academic Press, San Diego, CA, 1992).
Within the scope of the invention, the term also encompasses any covalently bonded carriers, which release the active compound in vivo when administered to an animal. Prodrug modifications of a compound often offer advantages of solubility, bioavailability, absorption, tissue compatibility, tissue distribution, or delayed release in the mammalian organism. While the prodrug derivatives of compounds of the invention have groups cleavable under metabolic conditions, for example, pharmaceutically acceptable esters, or amides, it is to be understood that such cleaving does not refer to cleaving of a bond between moieties L and M and/or V and M in the general formula L- M-V. The cleavable groups being different from L, M and V can be cleaved enzymatically or non- enzymatically, or hydrolytically to the free hydroxy, carboy, or amino group of the active parent compound.
The prodrug may also be a reduced form, which is oxidized in vivo to the therapeutic compound, for example, an alcohol to a carboxylic acid.
Thus, the present invention provides compounds, salts thereof (being pharmaceutically acceptable or unacceptable), internal salts thereof, hydrates thereof, polymorphs thereof, prodrugs thereof and mixtures of any one form thereof.
Pure compounds may be obtained following methods of purification as known in the art. Where the reaction product is a mixture of isomers, specific isomers may be separated by means of classical separation techniques, such as chromatographic or crystallization methods, or by other methods known in the art, such as through, formation of diastereomeric salts, for example by salt formation with an enantiomerically pure chiral acid, or by means of chromatography, for example by using chromatographic materials modified with chiral ligands.
The compounds of the invention, as shown herein are modulators of the glutamate NMDA receptor. Within the scope of the present application, the term "modulator" refers to the ability of compounds of the invention to affect (alter) the activity of the glutamate NMDA receptor. The receptor may be over or under activated in response to treatment with one or more of the compounds of the invention. The over- or under-activation of the receptor may be determined by e.g., a functional assay or other in vitro, in vivo, and/or ex-vivo tests such as those demonstrated hereinbelow or such as those known to a person skilled in the art. Thus, in some embodiments, the compounds of the invention are agonists, namely having the ability to activate the glutamate NMDA receptor, or partial agonists, namely only partially activating the receptor. In some other embodiments, the compounds are antagonists, namely having the ability to block or arrest the activity of the glutamate NMDA receptor, or partial antagonist.
In another aspect, the present invention provides the use of at least one compound (or a salt, prodrug, or a stereoisomer thereof) according to the invention for the preparation of a composition. In some embodiments, the composition of the invention is a pharmaceutical composition, comprising also at least one pharmaceutically acceptable carrier, diluent or excipient.
The pharmaceutical composition of the invention may comprise one or more compounds according to the invention. Where the composition comprises two or more compounds, the compounds may be compounds of different classes (e.g., one compound being a tricyclic psychotropic and the other an antidepressant), the compounds may be salt forms of the same compound (e.g., one compound being a sodium salt of Compound 1 and the other a potassium salt of Compound 1), different compounds in different or same form (e.g., one may be a salt and the other may be an ester), in different or same concentrations, etc.
The choice of carrier will be determined in part by the particular compound, as well as by the particular method used to administer the composition comprising it. Accordingly, there is a wide variety of suitable formulations of the pharmaceutical composition of the present invention. The following formulations for oral, aerosol, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal, and vaginal administration are merely exemplary and are in no way limiting.
Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
Capsule forms can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch.
Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodiumk talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers.
Lozenge forms can comprise a compound of the invention in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to a compound of the invention, such carriers as are known in the art.
The compounds of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer Foπrmlations suitable for parenteral administration include aqueous and nonaqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The compound can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, glycerol ketals, such as 2,2-dimethyl-l,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carboniers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxy- ethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-β-aminopriopionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (3) mixtures thereof.
The parenteral formulations will typically contain from about 0.5 to about 25% by weight of the compound of the invention in solution. Suitable preservatives and buffers can be used in such formulations. In order to minimize or eliminate irritation at the site of injection, such compositions ma3' contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations ranges from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
The compounds of the present invention may be made into injectable formulations. The requirements for effective pharmaceutical carriers for injectable compositions are well known to those of ordinary skill in the art. See Pharmaceutics and Pharmacy Practice, J.B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622-630 (1986).
The compositions of the invention may comprise at least one compound or a pharmaceutically acceptable salt or derivative thereof and in addition comprise a carrier. Additionally, the composition may comprise at least one drug selected from CNS depressants, CNS stimulants, and drugs that selectively modify CNS function, such as anticonvulsants, anti-Parkinsonian drugs, opioid and non-opioid analgesics, appetite suppressants, antiemetics, analgesic-antipyretics, certain stimulants, antidepressants, antimanic agents, antipsychotic agents, sedatives and hypnotics.
The pharmaceutical compositions of the invention may be administered to a subject, a human or non-human, via any of the administration routes disclosed hereinbefore. The pharmaceutical compositions may be used in a treatment regime of a disease or disorder of choice, as known to a medical practitioner, hi some embodiments, the disease or disorder is a psychological or psychiatric disease or disorder.
Thus, the present invention also provides a use of a compound according to the invention in the treatment of a disease or disorder. The invention further provides a method of treating a disease or disorder comprising administering to a subject in need thereof a compound or a composition according to the present invention.
In some embodiments, said disease or disorder is a psychiatric disease or disorder. In some other embodiments, said disease or disorder is associated with modulation of the activity of the glutamate NMDA receptor. Non-limiting examples of such diseases and disorders are diseases and disorders of the CNS, such as psychotic disorders, anxiety disorders, dissociative disorder, personality disorders, mood disorders, effective disorder, neurodegenerative disorders, convulsive disorders, boarder line disorders and mental diseases and disorders.
In other embodiments, the disease or disorder is selected from Schizophrenia, bipolar disorders (and maintainance for bipolarity), psychotic depression, delussional disorders, conduct disorders, psychosis-induced dementia, organic psychosis, mood disorders, Torte's syndrome, depression, post-traumatic stress disorder, anxiety, panic disorder and Alzheimer's disease.
The invention further provides a method of modulating the activity of the glutamate NMDA receptor, said method comprising contacting a tissue (e.g., a CNS tissue) expressing said glutamate NMDA receptor with at least one compound or a composition according to the invention. The tissue being contacted with the at least one compound or composition according to the invention may be a tissue extracted or removed from the body of the animal (ex vivo) or a tissue in the body of the animal (in vivo).
In some embodiments, said activity is enhanced. In some other embodiments, said activity is decreased.
Also provided by the present invention is a method for modulating one or more biological and/or pharmacological pathways, whereby said modulation ensues the treatment of an at least one psychological and/or psychiatric disease or disorder or the preventing of such a disease or disorder, said method comprising administering to a subject an effective amount of a compound or a composition according to the present invention.
As used herein, the term "effective amount" refers to an amount of a compound of the invention, or a composition comprising thereof which is effective in treating at least one disease or disorder as defined. The amount must be effective to achieve the desired therapeutic effect as described, i.e., of the activity of the glutamate NMDA receptor, depending, inter alia, on the type and severity of the disease to be treated and the treatment regime. The effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount. As generally known, an effective amount depends on a variety of factors including the affinity of the ligand to the receptor, its distribution profile within the body, a variety of pharmacological parameters such as half-life in the body, on undesired side effects, if any, on factors such as age and gender, etc.
The term "treatment or any lingual variation thereof, as used herein, refers to the administering of a therapeutic amount of the compound of the invention or a composition comprising thereof which is effective to ameliorate undesired symptoms associated with a disease, to prevent the manifestation of such symptoms before they occur, to slow down the progression of the disease, slow down the deterioration of symptoms, to enhance the onset of remission period, slow down the irreversible damage caused in the progressive chronic stage of the disease, to delay the onset of said progressive stage, to lessen the severity or cure the disease, to improve survival rate or more rapid recovery, or to prevent the disease form occurring or a combination of two or more of the above.
BRIEF DESCRIPTION OF THE DRAWINGS
In order to understand the invention and to see how it may be carried out in practice, embodiments will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:
Figs. IA-D show the open filed results following i.p. administration of Compound 1 at 12.5, 25, 50, 75 and 100 mg/kg (each point is the mean +/- SEM of 3-5 determinations). Fig. IA shows the effect on distance moved; Fig. IB shows the effect ion velocity; Fig. 1C shows the effect on rearing frequency; and Fig. ID shows the duration of the "not moving" periods.
Figs. 2A-D show (each point is the mean +/- SEM of 6 determinations) the dose- dependent effect of Compound 6 (PGW-5) on the motility of mice. Fig. 2A shows the effect on distance moved; Fig. 2B shows the effect on velocity mean; Fig. 2C shows the effect on rearing frequency; and Fig. 2D shows the total duration of the "not moving" periods.
Figs. 3A-C show the effect of oral administration of Compound 1 on the horizontal and vertical behavior of mice. Fig. 3A shows the effect on the distance moved; Fig. 3B shows the effect on velocity; and Fig. 3C shows the effect on number ofrearings.
Figs. 4A-C show the effect of Compound 3 (PGW-7) (12.5, 25 and 50 mg/kg, each point is the mean +/- SEM of 6 determinations) in the open filed test. Fig. 4A shows the effect on the distance moved; Fig. 4B shows the effect on the total duration of "not moving" periods and Fig. 4C shows the effect on the rearing frequency.
Fig. 5 shows the effect of Compound 1, olanzapine and D-serine (20mg/kg, p.o) on time spent in the center of an open filed and on frequency to the center.
Figs. 6A-B show the effect of Compound 1 (20mg/kg, p.o.) on amphetamine- induced hyperactivity as manifested by the total number ofrearings and climbings over a period of lhr (Fig. 6A) and the effect of Compound 1 (20mg/kg, p.o.) on number of head movements (Fig. 6B).
Figs. 7A-B show the effect of Compound 3 (PGW-7) (12.5, 25, 50 mg/kg, i.p.), amphetamine (2 mg/kg, i.p.) and a combination thereof in the Open field test on distance moved (Fig. 7A) and immobility total duration (Fig. 7B).
Figs. 8A-E show the effect of Compound 1 (PGW), MK-801 and a combination thereof in the open field test on the distance moved (Fig. 8A); velocity mean (Fig. 8B); strong mobility total duration(s) (Fig. 8C); "not moving" total duration (Fig. 8D); and rearing frequency (Fig. 9E).
Figs. 9A-D show the effect of Compound 1 (PGW-4) (administered i.p.) on inhibition of the hyperlocomotion effect of MK-801. Fig. 9A shows the distance moved total; Fig. 9B shows the velocity mean; Fig. 9C shows the effect of Compound 1, MK- 801 and a combination thereof on hi zone frequency; and Fig. 9D shows the effect of Compound 1, MK-801 and a combination thereof on in zone total duration.
Figs. 10A-D shows the effect of Compound 3 (PGW-7) (12.5, 25 and 50 mg/kg, i.p.) on hyperactivity-induced by MK-801 (0.15mg/kg, i.p.). Fig 1OA shows effect of Compound 3, MK-801, and a combination thereof on distance moved; Fig. 1OB shows the effect of Compound 3, MK-801, and a combination thereof on "not moving" total duration; Fig. 1OC shows the effect of Compound 3, MK-801, and a combination thereof on in-zone frequency (zone 3); and Fig. 1OD shows the effect of Compound 3, MK-801, and a combination thereof on in-zone total duration.
Fig. 11 shows the effect of Compound 1 (PGW) (30, 40 and 50 mg/kg, i.p.) on catalepsy.
Figs. 12 A-D show the effect of Compound 1 (PGW) (10, 20mg/kg, oral), in the forced swim test (FST) on distance moved (Fig. 12A); on velocity (Fig. 12B); on strong mobility (Fig. 12C); and on immobility (Fig. 12D).
Figs. 13A-C show the effect of Compound 1 (PGW-4) (10, 20, 30 mg/kg, oral) in the FST on immobility (Fig. 13A); on distance moved (Fig. 13B); and on strong mobility (Fig. 13C).
Figs. 14A-B show the effect of olanzapine in comparison to Compound 1 (PGW) in the FST on distance moved (Fig. 14A) and immobility (Fig. 14B).
Figs. 15A-E show the effect of Compound 1 (PGW-4) and diazepam in the elevated plus maze test on mice frequency in-zone (Fig. 15A); on total duration in zone (Fig. 15B); on velocity (Fig. 15C); and rearing frequency (Fig. 15D). Fig. 15E shows the effect of Compound 6 (PGW-5) in the elevated plus maze test.
Fig. 16 shows the effect of 10 and 20 mg/kg of Compound 1 (PGW-4), administered p.o. on latency to platform.
Fig. 17 shows the effect of acute treatment of Compound 1 at 10 and 20 mg/kg given p.o. on the spatial cognitive tasks in the Morris Water Maze in rats pretreated with MK-801.
Fig. 18 shows the effect of acute use of Compound 6 at 10 mg/kg given p.o. on the spatial cognitive tasks in the Morris Water Maze in rats pretreated with MK-801.
Fig. 19 shows the effect of Compound 1 on the mice body weight.
Fig. 20 shows the effect of treatments with different drugs on glioma viability.
DETAILED DESCRIPTION OF THE INVENTION A. SYNTHESIS OF NOVEL COMPOUNDS
The compounds of the invention may be prepared according to a variety of procedures, as disclosed and exemplified herein. One general way to prepare the compounds of the general formula (A), substituted with the appropriate amino acid, e.g., glycinyl, serinyl or sarcosinyl moieties directly or through a linker, as shown in the specific structures herein, is to first prepare the demethylated derivatives of the parent CNS-active agents (e.g. des-Me-olanzapine, cfes-Me-clozapine). These can be prepared by coupling two ørt/rø-disubstituted aromatics: one bearing a nitro group in an ortho position to a good leaving group (e.g., fluoride, chloride), while another is an ortho- cyano aromatic amine, phenol or thiophenol. The coupling (for example through an aromatic nucleophilic substitution) forms a nitro cyano-diarylamine, nitro cyano- diarylether, or nitro cyano-diarylthioether. In the next stage, the nitro group is reduced to amine with a simultaneous central diazepine ring closure. The formed tricyclic amidine reacts with piperazine, forming the des-Me form of the L fragment of the target compound, as disclosed and exemplified herein.
The piperazine secondary amine of this intermediate can be further reacted with a β-iodo-alanine, or dehydroalanine derivative (where the linker moiety is absent) or with 0-iodoalkyl serine derivatives (where the linker moiety is present). The amine of the aminoacid moiety may be protected utilizing any protecting groups known to the person skilled in the art. Typically, in the following examples, the amine was protected with the Boc-protecting group. Deprotection at the final step with an acid such as HCl, afforded the desired active compound in the trihydrochloride salt form.
It should be noted that the following examples are non-limiting in nature and are presented for the full understanding of the invention. The synthetic procedures provided may be varied mutatis mutandis and other novel compounds of the general formulas disclosed herein may be prepared.
Synthesis of Compound 1
(1) Synthesis of 2-Amino-5-methyl-3-thiophenecarbonitrile (A) For a general synthesis see He, X.; Griesser, U. J.; Stowell, J. G.; Borchrdt, T. B.; Byrn, S. R. J. Pharm. Sci. 2001, 90, 371.
Figure imgf000033_0001
A
Sulfur (S8, 0.9 g, 0.0 27 mmol), propionalaldehyde (2 ml, 0.027 mmol) and DMF (6 ml) were transferred to a three-necked round-bottomed flask equipped with a dropping funnel and condenser. The resulting mixture was cooled to 0°C, and triethylamine (2.3 ml) was added in a dropwise manner via the dropping funnel. The resulting dark solution was then warmed to room temperature over a period of 1 h. A solution of malononitrile (1.71 ml, 1.8 g, 0.027 mmol) in DMF (3.2 ml) was transferred to the addition funnel and added in a dropwise manner. The resulting brownish mixture was stirred overnight at room temperature. Then the mixture was poured over 80 ml of ice and water to yield an orange precipitate. The solid A was filtered, washed with chilled water, and dried in vacuo; yield 78%.
1H NMR (200 MHz, CDCl3): δ 6.35 (s, IH), 4.15 (br s, 2H), 2.27 (s, 3H). 13C NMR (50 MHz, CDCl3): δ 160.9, 146.3, 124.6, 122.0, 115.7, 14.9.
(2) Synthesis of 2-(2-nitroanilidoV5-methyl-3-thiophenecarbonitrile (B) For a general synthesis see He, X.; Griesser, U. J.; Stowell, J. G.; Borchrdt, T. B.; Byrn, S. R. J. Pharm. Sd. 2001, 90, 371.
Figure imgf000034_0001
B
To NaH (3 equivalents, from 55% suspension in oil, rendered oil-free by washing with hexane) was added 1 ml of dry THF. 2-amino-5-methyl-3- thiophenecarbonitrile (A, as prepared above, 0.5 g, 3.6 mmol) and 4-fluoro-3- nitotoluene (0.51 g, 3.6 mmol) were dissolved in dry THF (1.5 ml) and added in a dropwise manner to the suspension while the temperature was maintained below 30°C. The reaction mixture was allowed to stir overnight under N2 purge. The mixture was then poured into 11 ml of ice- water mixture, neutralized with concentrated HCl, and extracted with 36 ml of DCM. The DCM solution was dried over MgSO4 and evaporated to dryness. The residue was purified by flash chromatography on silica gel (elution with 1 :9 EtOAc/ Hexanes) to give compound B (yield 60%).
1H NMR (200 MHz, CDCl3): δ 9.61 (br s, IH), 8.25 (dd, J = 8.5 Hz, J = 1.5 Hz, IH), 7.52 (dt, J = 7.8 Hz, J = 1.4 Hz, IH), 7.19 (dd, J = 8.5 Hz, J = 1.1 Hz, IH)5 6.97 (dt, J = 7.8 Hz, J = 1.2 Hz5 IH), 6.78 (d, J = 1.1 Hz, IH), 2.48 (s, 3H). (3) Synthesis of 4-amino-2-methyl-10H-thienof2,3-bl|"l,51benzodiazepine, hydrochloride salt (C)
For a general synthesis see Chakrabarti, J. K.; Hotten, T. M.; Pullar, I. A.; Steggles, D. J. J. Med. Chem. 1989, 32, 2375.
Figure imgf000035_0001
B
To a slurry of B (100 mg, 0.4 mmol) in ethanol (ImI) was added tin(II)- chloride-dihydrate (260 mg, 1.16 mmol) in concentrated HCl (ImI), the solution was heated to reflux for 3 h and cooled overnight, and the solid C was filtered, washed with chilled DCM, and dried in vacuo; yield 95%.
1H NMR (200 MHz, DMSOd6): δ 11.05 (s, IH), 9.53 (s, IH), 9.08 (br s, IH), 8.82 (br s, IH), 6.80 - 7.14 (m, 4H), 6.78 (s, IH), 2.23 (s, 3H).
(4) Synthesis of 2-methyl-4-α-piperazinyl)-10H-thienor2.3-bin.51benzo diazepine (D)
For a general synthesis, see Chakrabarti, J. K.; Hotten, T. M.; Pullar, I. A.; Steggles, D. J. J. Med. Chem. 1989, 32, 2375.
Figure imgf000035_0002
C D Starting material C (prepared according to the above, 140 mg, 0.53 mmol) was added to a mixture of dry dimethyl sulfoxide (1 ml), dry toluene (1 ml), and piperazine (140 mg, 1.6 mmol). The stirred solution was then heated at 125°C under nitrogen for 5 h and cooled to room temperature. Then distilled water (2 ml) was added, while the temperature is kept below 25°C. After stirring at 5°C for 30 minute, the suspension was cooled overnight and the solid D was filtered, washed with chilled water, and dried at 70°C under reduced pressure; yield 69%.
1H NMR (200 MPIz, CDCl3): δ 6.80 - 7.06 (m, 3H), 6.60 (dd, J = 7.4 Hz, J = 1.3 Hz, IH), 6.30 (d, J = 0.8 Hz, IH), 5.01 (s, IH), 3.48 (m, 4H), 2.95 (m, 4H), 2.31 (s, 3H).
(5) Synthesis of 2-tert-butoxycarbonylamino-3-[4-r2-methyl-10H-thieno[2,3- b]|"l,51 benzodiazepine -4-yl)-piperazin-l-yl~|-propionic acid, methyl ester (E)
Figure imgf000036_0001
D E
A mixture of D (200 mg, 0.67 mmol), Boc-iodo- AIa-OMe (220 mg, 0.67 mmol) and Na2CO3 (71 mg, 0.67 mmol) in dry acetone (17 ml) was refiuxed overnight under nitrogen. The solvent was evaporated, the residue diluted with dry methanol (2 ml, distilled from magnesium), and the reaction mixture was stirred under N2 overnight at 45°C. Methanol was evaporated. Chromatography on silica gel afforded E by elution with 1:1 EtOAc: hexanes; yield 48%.
1H NMR (400 MHz, CDCl3): δ 7.03 (d, J = 7.6 Hz, IH), 6.95 (t, J = 7.6 Hz, IH), 6.87 (t, J = 7.6 Hz, IH), 6.61 (d, J = 7.5 Hz, IH), 6.26 (s, IH), 5.32 (br s, IH), 4.35 (br m, IH), 3.74 (s, 3H), 3.49 (br s, 4H), 2.73 (br m, 2H), 2.53 (br m, 4H), 2.30 (s, 3H), 1.45 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 172.6, 157.7, 155.5, 152.4, 142.9, 140.1, 129.1, 128.0, 124.6, 124.0, 122.8, 119.1, 80.0, 58.8, 53.2, 52.3, 51.9, 47.0, 28.3, 15.4. (6) Synthesis of 2-ammo-3-r4-(y2-methyl-10H-thienof2.3-bl[l,51beDzodiazeρin- 4-yl)-piperazin-l-yll-propionic acid, methyl ester hydrochloride salt ("Compound 1- salf)
Figure imgf000037_0001
E Compound 1
A mixture of E '(80 mg, 0.16 mmol) and HCl/methanol (1.25 M5 2 ml) was stirred overnight. After evaporating the solvent, the residue was diluted with water and washed with ether. The aqueous solution was evaporated to dryness to give the protonated Compound 1; yield 92%.
1H NMR (400 MHz, D2O): δ 6.99 (dt, J = 7.4 Hz, J = 1.3 Hz, IH), 6.83 - 6.92 (m, 2H), 6.63 (d, J = 7.9 Hz, IH), 6.16 (s, IH), 4.50 (m, IH), 3.78 (br s, 4H), 3.66 (s, 3H), 3.58 (dd, J = 14.3 Hz, J - 6.2 Hz, IH), 3.34 (dd, J = 14.3 Hz, J = 6.3 Hz, IH), 3.28 (br s, 4H), 2.02 (s, 3H). 13C NMR (100 MHz, D2O): δ 167.4, 164.2, 160.5, 147.1, 132.3, 129.3, 127.2, 125.7, 125.1, 121.9, 120.1, 109.7, 55.1, 54.4, 52.1, 48.3, 47.5, 14.3. MS (FAB): calcd. for C20H26N5O2S (MH+) 400.1, found 400.1.
Synthesis of Compound 2
(1) Synthesis of N-Boc-L-serine, ethyl ester (F)
Figure imgf000037_0002
To a solution of Boc-Ser-OH (0.3 g, 1.46 mmol, 1 eq) in dry DMF (4ml) at 00C, dry K2CO3 (0.22 g, 1.6 mmol, 1.1 eq) was added. The resulting white suspension was stirred for 15 minute and ethyl iodide (0.68 g, 0.35 ml, 4.38 mmol, 3 eq) was dropwise added. The cooling was removed and reaction mixture was stirred at room temperature under N2 for 24h. To the formed white emulsion H2O was added, and the mixture extracted by EtOAc. The combined organic layer was washed by H2O and then brine, and dried over MgSO4. The solvent was evaporated and the obtained oil was dried overnight in high vacuum. Yield of the pure F - 0.27 g (79%).
1H NMR (400MHz, CDCl3): δ 5.55(d, IH)5 4.27(m, IH), 4.16(q, J = 8.0 Hz5 J= 6.2 Hz5 2H), 3.79-3.90(m5 2H)5 3.24(br s, IH)5 1.39 (s, 9H) 1.25(t, J= 14.2 Hz, 3H).
(2) Synthesis of N-Boc-dehvdroalanine, ethyl ester (G)
Figure imgf000038_0001
To a solution of Boc-L-serine ethyl ester, F, as prepared above, (0.45 g, 1.9 mmol, 1 eq) in dry DCM (10 ml) under N2, triethylamine (0.3 ml, 2.1 mmol, 1.1 eq) was added and then dichloro-acetylchloride (0.2 ml, 2.1 mmol, 1.1 eq) was added dropwise. The reaction mixture was stirred at room temperature for 1 h and then the solution of DBU (0.31 ml, 2.1mmol5 1.1 eq) in 2.5 ml of dry DCM was added. The dark blue solution was refluxed overnight under N2 The cooled reaction mixture was poured to 5% citric acid solution in H2O5 extracted by DCM and the combined organic layer was washed by brine, dried over MgSO4 and evaporated. The black oil residue was dried in high vacuum and yielded 0.5 g of intermediate dichorroacetyl derivative. This product was dissolved in 3 ml of dry DCM5 then DBU (0.33 ml) in 2 ml DCM was added and reaction mixture was refluxed under N2 overnight. The cooled solution was poured to 5% aqueous citric acid solution and extracted by DCM. The organic layer was washed with brine, dried over MgSO4 and evaporated. The resulting black oil was purified by flash chromatography on silica gel (eluent - 3% EtOAc in Hexanes). Yield of the colorless oil product - 0.23g (58%)
1H NMR (200 MHz, CDDl3): δ 7.0(s, IH), 6.1(s, IH) 5.69(s, IH)5 4.24(q, J = 14.2 Hz, 2H) 1.45(s, 9H), 1.29(t, J= 7.1 Hz, 2H). (3) Synthesis of 2-(N-Boc)amino-3-r4-(2-methyl-10H-thieno[2,3-biπ,51benzo diadizepin-4-yl)-piperazin-l-yl] -propionic acid, ethyl ester ("H)
Figure imgf000039_0001
D H
A mixture of 2-methyl-4-( 1 -piperazinyl)- 1 OH-thieno [2,3 -b] [ 1 ,5]benzodiazepine, compound D above, (0.14 g, 0.46 mmol, 1 eq) and N-Boc-dehydroalanine ethyl ester (G, 0.1 g, 0.46 mmol, 1 eq) in 4 ml of anhydrous EtOH was refluxed at 60-65 °C overnight. The solvent was evaporated to dryness and the crude product was purified by flash chromatography (eluent - 40% EtOAc in Hexanes). Yield - 0.15g (65%)
1H NMR (400 MHz, CDCl3): δ 6.95-7.01(m, 2H); 6.86(m, IH); 6.60(d, J = 7.9 Hz5 IH); 6.26(s, IH); 5.35(br s, IH); 4.33(br s, IH); 4.16-4.20(m, 2H); 3.46(br s, 4H); 2.73(br s, 2H); 2.53-2.58(m, 4H); 2.22(s5 3H); 1.45(s, 9H); 1.29(t5 J- 7.1 Hz, 3H). 13C NMR (100MHz, CDCl3): δ 172.9, 158.4, 156.2, 152.6, 143.3, 141.6, 129.9, 128.9, 125.4, 124.6, 123.7, 120.2, 119.7, 80.7, 62.1, 59.7, 54.1, 52.8, 47.6, 29.1, 16.2, 14.9.
(4) Synthesis of 2-Arnino-3-r4-(2-methyl-10H-tbieno[2,3-biri.51-benzo diazepine-4-yl) piperazin-1-yl] propionic acid, ethyl ester trihydrocbloride salt (Compound 2)
Figure imgf000039_0002
H Compound 2 A mixture of 2-(N-Boc)amino-3-[4-(2-methyl-10H-thieno[253-b][l,5]benzo diadizepin-4-yl)-piperazin-l-yl] -propionic acid, ethyl ester, H, (50 mg, 0.096 mmole) and HCl/ethanol (1.25 M, 2 ml) was stirred overnight at room temperature. The solvent was evaporated, the residue was diluted with water and washed with diethylether. The aqueous solution was lyophilized. Yield of Compound 2- 30 mg (60%).
1H NMR (400MHz, CDCl3): δ 7.20-7.15(m, IH); 7.03-7.13(m, 2H); 6.85(d, J = 8.0 Hz, IH); 6.37(s, IH); 4.37(m, IH); 4.23(q, J= 8.0 Hz, 2H); 3.78(br s, 4H); 3.26(dd, J = 12.0 Hz, J= 8.0 Hz, IH); 3.10(m, 2H); 2.97(br s, 4H); 2.19(s, 3H); 1.20(t, J= 8.0 Hz5 3H). 13C NMR (IOOMHZ, CDCl3): δ 168.8, 163.8, 160.7, 147.8, 132.9, 129.9, 128.2, 126.3, 125.9, 122.9, 120.8, 111.2, 64.9, 56.2, 52.7, 50.6, 15.0, 13.8. MS (Fab): calcd. for C2IH28N5O2S (MH+) 414.4, found 414.2.
Synthesis of Compound 6
(1) Synthesis of N-Boc-N-methyl-L-serine, methyl ester (T)
Figure imgf000040_0001
To a solution of Boc-N-Me-L-serine (0.5 g, 2.2 mmol, 1 eq) in dry DMF (2 ml) at 0°C dry K2CO3 (0.35 g, 2.5 mmol, 1.2 eq) was added. The resulting white suspension was stirred for 15 minutes and methyl iodide (0.93 g, 0.42 ml, 6.6 mmol, 3 eq) was dropwise added. The cooling was removed and reaction mixture was stirred at room temperature under N2 for 24 h; the progress of the reaction was monitored by TLC (EtOAc/Hexanes 4:6). To the formed white emulsion H2O was added, and the mixture extracted by EtOAc (three times x 30ml). The combined organic layer was washed by H2O and then brine, dried over MgSO4. The solvent was evaporated and the obtained colorless oil was dried overnight in high vacuum. Yield of the pure product 1 - 0.4 g (76%).
Two aptamers are visible in NMR. 1N NMR (400 MHz, CDCl3); δ 4.47(m, IH)5 4.03(m, 2H), 3.75 - 3.83(m, 2H), 3.13(m, IH), 3.69(s, 3H), 2.89(s, 3H), 2.85(s, 3H), 1, 41(s, 9H)5 1.37(s, 9H). 13C NMR (100 MHz, CDCl3): δ 170.0, 170.6, 156.2, 154.9, 80.4, 80.2, 62.1, 61.I5 60.7, 60.6, 33.7, 33.I5 28.0. (T) Synthesis of N-Boc-N-methyl dehydroalanine, methyl ester (J)
Figure imgf000041_0001
To a solution of Boc-N-methyl-L-serine methyl ester, I5 (0.46 g, 1.9 mmol. 1 eq) in 10 ml dry DCM under N2, triethylamine (0.29 ml, 2.2 mmol, 1.15 eq) was added and then dichloroacetylchloride (0.23 ml, 2.2 mmol, 1.15 eq) was added dropwise. The reaction mixture was stirred at room temperature for 1 h, then the solution of DBU (0.33 ml, 2.2 mmol, 1,15 eq) in 2.5 ml dry DCM was added, and the combined mixture was refluxed overnight.
The cooled reaction mixture was poured to 5% citric acid solution in H2O, extracted by DCM, and the separated organic layer was washed by brine, dried by MgSO4 and evaporated. The black oil residue (0.52g) of the intermediate dichloroacetyl derivative was dissolved in 3 ml dry DCM and DBU (0.33ml) in 2 ml DCM was added. The reaction mixture was refluxed under N2 overnight. The cooled solution was poured to 5% citric acid aqueous solution, extracted by DCM, and the organic layer was washed by brine, dried by MgSO4 and evaporated. The crude product was purified by flash chromatography on silica gel (elution with isocratic 10% EtOAc/Hexanes) to give the pure J - yield 0.2 g (48 %). Drying of the product in high vacuum should be avoided.
1H NMR (200 MHz, CDCl3): δ 5.77(s, IH), 5.30 (s, IH), 3.75(s, 3H), 3.09(s, 3H)5 1.39(s, 9H). 13C NMR (50 MHz5 CDCl3): δ 153.7, 141.3, 115.1, 80.9. 52.0, 36.4, 27.9. (3) Synthesis of 2-(N-Boc-N-methvnammo-3r4-(2-methyl-10H-tMeno[2.3-bl [l,5]benzodiazeρm-4-yl)piperazin-l-yl]propionic acid, methyl ester (K)
Figure imgf000042_0001
D K
A mixture of 2-methyl-4-(l-piperazinyl)-10H-thieno[2,3-b][l,5]benzodiazepine, compound D above, (0.28 g, 0.93 mmol, 1 eq) and Boc-N-methyl dehydroalanine methyl ester, J, (0.2 g, 0.93 mmol, 1 eq) in 5 ml anhydrous MeOH was heated at 500C under N2 overnight. The cooled solution was evaporated to dryness and the residue was purified by flash chromatography on silica gel (eluting with isocratic 50% EtOAc/Hexanes). Yield of pure K - 0.3 g (63%).
1H NMR (400 MHz, CDCl3): δ 7.03(d, J= 1.6 Hz, IH), 6.95(t, J= 7.6 Hz, IH), 6.87(t, J= 1.6 Hz, IH), 6.60(d, J= 7.5 Hz, IH), 6.29(s, IH), 5.02(m, IH) 4.98(s, IH), 4.57 (m, IH), 3.76(s, 3H), 3.47 (br s, 4H), 2.91 (br m, 2H), 2.84 (s, 3H), 2.68 -2.90 (br m, 4H), 2.31(s, 3H) 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 172.15, 157.99, 155.6, 152.1, 142.9, 141.3, 129.4, 128.5, 125.0, 124.1, 123.4, 113.9, 119.3, 80.8, 80.4, 58.0, 57.5, 56.5, 55.7, 53.6, 53.4, 52.5, 47.3, 28.8, 15.8.
(4) Synthesis of 2-N-methylamino-3-r4-('2-methγl-10H-thienor2.3-biri.51benzo diazepin-4-yl)-piperazin-l-yl] propionic acid, methyl ester trihydrochloride salt (Compound 6)
Figure imgf000043_0001
A solution of 2-(Η-Boc-N-me1±ιyl)amino-3[4-(2-methyl-10H-thieno[2,3- b][l,5]benzodiazepin-4-yl)piperazin-l-yl]ρropionic acid, methyl ester, K5 (0.3 g, 0.58 mmol) in HCL/ethanol (1.25 M5 8 ml) was stirred at room temperature overnight. The light yellow precipitate was formed and the suspension was decanted. The precipitate was washed several times with dry diethyl ether, and dried under vacuum. Yield of Compound 6 - 0.26 g (87%).
1H NMR (400 MHz5 D2O): δ 7.15(dq, J= 6.6 Hz5 J= 2.3 Hz5 IH)5 7.03-7.05(m, 2H)5 6.82(d, J = 7.8 Hz5 IH)5 6.32(s5 IH), 4.26(m, IH)5 3.72(br s, 4H), 3.73(s, 3H)5 3.30(dd, J = 14.3 Hz5 J = 5.7 Hz, IH)5 2.97 (br S5 4H), 2.74(s, 3H)5 2.17 (s, 3H). 13C NMR (100 MHz5 D2O): δ 167.6, 163.0, 159.7, 146.9, 131.9, 128.9, 127.16, 125.4, 124.9, 122.0, 119.8, 110.1, 57.0, 54.2, 53.9, 51.7, 48.6, 31.7, 14.1. MS (FAB): calcd. for C21H27N5O2S (MH+) 413.5, found 414.3. EA (%): calcd. for C2JH31Cl3N5O3S (M-3HC1-H2O): C 46.58, H5.91, Cl 19.65; found: C 45.94, H 6.18, Cl 19.52.
Synthesis of Compound 14
(1) Synthesis of O-AUyl-N-Boc-L-serine methyl ester (L)
Figure imgf000043_0002
To a stirred solution of N-Boc-L-serine methyl ester (0.22 g, 1 mmol, leq) in dry THF (2 ml) under N2 a mixture of π-allylpalladium chloride dimer (0.01 g, 0.02 mmol), triphenylphosphine (0.024 g, 0.09 mmol) and allyl ethyl carbonate (0.26ml, 2mmol, 2eq) in dry THF (1 ml) was dropwise added at room temperature.
The reaction mixture was refluxed under N2 overnight. The solvent was evaporated and the crude product was purified by flash chromatography on silica gel (elution with isocratic 10% EtOAc/Hexanes) to give the pure compound. Yield of L was 0.14 g (63%).
1H NMR (400 MHz, CDCl3): δ 5.75-5.85 (m, IH), 5.36 (m, IH), 5.13-5.23 (m, 2H) 3.93-3.95 (m, 2H), 3.82 (dd, J = 3.0 Hz, J= 6.4 Hz, IH), 3.72 (s, 3H), 3.61 (dd, J = 3.3 Hz5 J = 9.4 Hz5 IH), 1.44 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 171.0, 155.3, 133.8, 117.2, 79.7, 72.0, 69.7, 53.8, 52.2, 28.1.
(D Synthesis of O-(3-Iodopropyl)-N-Boc-L-serine methyl ester (M)
Figure imgf000044_0001
To a solution of O-Allyl-N-Boc-L-serine methyl ester, L prepared as above, (0.25 g,l mmol, 1 eq) in dry THF (1 ml) equimolar amount of IM BH3-THF complex solution in, THF (0.96 ml) was dropwise added at 0°C. After addition, the colorless solution was heated at 55°C under N2 for 1.5 h. The progress of the reaction was monitored by TLC (20% EtOAc/Hexanes). To a cooled reaction mixture (00C) I2 (0.17 g, 0.67 mmol) was added, followed by solution of NaOH in MeOH (0.24 ml, 3M). The formed dark solution was stirred under N2 at room temperature for 2 h.
The reaction mixture was then poured into a 1 M solution of sodium thiosulfate in H2O and extracted by EtOAc (three times with 20 ml). The combined organic layer was washed by brine and dried over MgSO4. The solvent was evaporated and the crude was purified by flash chromatography on silica gel (elution with isocratic 20% EtOAc/Hexanes) to give the pure M in 25% yield (0.093 g).
1H NMR (400 MHz, CDCl3): δ 5.32 (d, J = 8.0 Hz, IH), 4.4 (m, IH), 3.81 (dd, J = 3.2 Hz, J = 9.4 Hz, IH), 3.66 (s, 3H), 3.64 (dd, J= 3.2 Hz, J = 9.4 Hz, IH), 3.44-3.51 (m, 2H), 3.19 (t, J = 6.6 Hz, 2H), 1.98 (quint, J = 6.1 Hz5 2H), 1.44 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 171.8, 156.2, 80.7, 71.6, 71.3, 70.7, 54.7, 53.3, 33.7, 29.0, 3.2.
(3) Synthesis of 2-m-Boc-ammo)-3-rO-propyl-3-f4-f2-methyl-10H-tliienor2.3- biri,51benzodiazepine-4-yl)piperaziii-l-yl]propionic acid, methyl ester (N)
Figure imgf000045_0001
D N
A mixture of 2-methyl-4-(l-piperazinyl)-10H-thieno[2,3-b][l,5]benzodiazeprne, (compound D, 0.073 g, 0.24 mmol, 1 eq), O-(3-Iodopropyl)-N-Boc-L-serine methyl ester (M, 0.093 g, 0.24 mmol, 1 eq) and dry Na2CO3 (0.025 g 0.24 mmol, 1 eq) in 8 ml anhydrous acetone was refluxed under N2 overnight. The cooled reaction mixture was evaporated to dryness; 20 ml CHCl3 was added to the residue and the precipitate of NaI was filtered off. The solvent was evaporated and the crude product was purified by flash chromatography on silica gel (eluting with gradient: 3% MeOH in CHCl3 to 5% MeOH in CHCl3) to give the pure N. Yield 0.1 g (77%).
1H NMR (400 MHz, CDCl3): δ 7.04 (d, J = 7.6 Hz, IH), 6.97 (t, J = 7.6 Hz, IH), 6.95 (t, J = 7.6 Hz, IH), 6.62 (d, J = 7.6 Hz, IH) 6.28 (d, J = 0.9 Hz, IH), 5.48 (d, J = 8.4 Hz, IH), 5.01 (s, IH), 4.42 (m, IH), 3.84 (dd, J = 9.3 Hz, J = 2.6 Hz, IH), 3.75 (s, 3H), 3.63 (dd, J = 9.5 Hz, J = 3.2 Hz, IH), 3.57 (m, 4H), 3.47 (m, 2H), 2.55 (m, 4H), 2.46 (m, 2H), 2.30 (s, 3H), 1.77 (quint, J = 6.6 Hz, 2H), 1.45 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 172.1, 158.3, 156.3, 152.5, 143.2, 141.7, 129.8, 128.8, 125.4, 124.5, 123.7, 120.3, 119.7, 80.8, 71.5, 70.5, 55.9, 54.8, 53.9, 53.2, 47.5, 29.1, 27.5, 16.2. (4) Synthesis of 2-Ammo-3-rθ-proρyl-3-(4-f2-methyl-10H-tMeno[2.3,-b11T,5'l- benzodiazepine-4-yl)piperazin-l-yl]propionic acid, methyl ester, trihydrochloride salt (Compound 14)
Figure imgf000046_0001
N Compound 14
A mixture of 2-(N-Boc-amino)-3-[O-ρropyl-3-(4-(2-methyl-10H-thieno[2,3- b][l,5] benzodiazepine-4-yl)-piperazin-l-yl]propiorύc acid, methyl ester, N, (100 mg, 0.18 mmol) and HCl/MeOH (1.25M, 3 ml) was stirred overnight at room temperature. The solvent was evaporated; the residue was diluted with water and washed with diethyl ether. The aqueous solution was lyophilized. Yield of Compound 14: 78mg (95%).
1H NMR (400 MHz5 D2O): δ 7.19-7.23 (m, IH), 7.05-7.11 (m, 2H), 6.87 (d, J = 8.0 Hz, IH), 6.41 (s, IH), 4.30 (t, J = 3.9 Hz, IH), 3.93 (dd5 J = 4.3 Hz, J = 11.0 Hz, 2H)5 3.81 (dd, J= 3.2 Hz5 J = 11.0 Hz5 2H)5 3.76 (s, 3H)5 3.75 (br s, 4H)5 3.57 (m, 2H), 3.26 (m, 6H)5 2.22 (s, 3H)5 1.98 (m, 2H). 13C NMR (100 MHz5 D2O): δ 169.46, 165.2, 161.7, 148.0, 133.4, 130.2, 128.0, 126.4, 126.1, 122.5, 120.9, 110.8, 68.7, 68.2, 55.3, 54.5, 53.8, 51.7, 47.6, 24.3, 15.0. MS (FAB): calcd for C23H3iN5O3S (MH+) 457.5, found 458.2.
B. ANIMAL BEHAVIORAL MODELS
In the following tests, unless otherwise indicated, male ICR or Balb/C mice, 6 to 8 weeks of age were used. All animals were housed (4-5/cage) under controlled conditions (temperature, light, humidity) given food and water ad libitum and allowed for 5-7 days of acclimatization before the beginning of experimentation. Compound of the invention such as Compounds 1, 3 or 6, or olanzapine were administered orally to the mice at an equimolar dose and the behavioral tests were performed 1-4 hr later. The following tests were performed:
(a) A forced swim test,
(b) An open field exploration, and
(c) An amphetamine-induced hyperactivity.
The forced swim test and the open field exploration tests were documented by a digital video camera linked to behavioral analysis software (Noldus Information Technology, Netherlands).
Forced Swim Test (FST)
This is one of the most widely used tools for screening antidepressant activity pre-clinically in acute treatment. The test was first described by Porsolt et al., (Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229, pp. 327-336, 1977). The FST test is based on the observation that rats and mice develop an immobile posture when placed in an inescapable cylinder of water. This behavior is considered a behavioral despair as opposed to active form of coping with stressful conditions. The FST test is considered a good screening tool with good reliability and predictive validity.
Three parameters were defined in the evaluation of FST:
1. Immobility- defined in the traditional Porsolt test as when no additional activity is observed other than that required to keep the animal's head above water;
2. Swimming behavior- being the movement (usually horizontal) throughout the chamber that also includes crossing into another quadrant;
3. Climbing behavior- being defined as the upward-directed movements (vertical) of the forepaws along the side of the swim chamber.
The test in mice was conducted acutely (60-90 minutes post oral drug administration) and animals were dropped to the cylinder for 6 minutes and scoring was performed in the last 4 minutes after 2 minutes of adaptation.
Round glass cylinders, 18 cm in diameter and 20 cm deep were used. Water temperature was 24-28°C. Four parameters were taken: immobility, velocity, distance and strong mobility. The immobility in the animals was defined by activity lower than 10% movement of the center of gravity of the animal. Swirnming was defined by the distance and the velocity of the animal, and climbing was related to strong mobility (movement of center of gravidance more than 30%).
Open field exploratory locomotor activity
The procedure consists of subjecting an animal, usually a rodent, to an unknown large environment from which escape is prevented by surrounding walls. The open field test is now one of the most popular procedures in animal psychology (Crawley, et al., Exploratory behavior models of anxiety in mice, Neurosci Biobehav Rev 9 (1985), pp. 37-44). The procedure involves forced confrontation of a rodent with the situation. The animal is placed in the center or close to the walls of the apparatus and the following behavioral items are recorded for a period ranging from 5 to 20 minutes: horizontal locomotion, and frequency of rearing or leaning. In such a situation, rodents spontaneously prefer the periphery of the apparatus to activity in the central parts of the open field. Increase in time spent in the central part as well as of the ratio central/total locomotion or decrease of the latency to enter the central part are indications of anxiolysis.
In a typical test, an individual mouse was placed in a novel environment of a square open field (50 x 50 cm), the floor of which had been divided into 3 areas, as shown below. The area within 10 cm of the chamber walls was termed the periphery. Animals were treated with a compound of the invention such as Compound 1, 3 or 6 with olanzapine or with a vehicle. One hour after drug administration, the animal was placed in the same corner of the field. The animal behavior in the open field was recorded by videotaping for 20-60 minutes and analyzed subsequently digitally using the Noldus software for animal behavior. The measurements included velocity, distance moved, frequency of visits to the central area, number of rearing events.
Figure imgf000048_0001
Amphetamine -induced hyperactivity
The amphetamine-induced hyperactivity and motility is one of the most popular animal models for schizophrenia (Pouzet B, et al, Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol Biochem Behav Apr; 71(4):655-665, 2002 and Geyer, et al., Animal behavior models of the mechanisms underlying antipsychotic atypicalicity, Progress in Neuro-Psychopharmacol & Biological Psychiatiy, 27, 1071-79, 2003). Amphetamines are known to augment dopaminergic and noradrenergic neurotransmission by inducing catecholamine release and preventing catecholamine reuptake
The experiment was conducted with ICR male mice placed in individual barrels. Olanzapine, or Compound 1 (for example at a dose of 10 and 20mg/kg) were administered interperitoneal' (i.p.) to the mice 0.5 hour prior to subcutaneous (s.c.) administration of amphetamine (3mg/kg). The locomotor activity, number of rearings and head movements was recorded every 15 minutes for 2 h.
MK-801-induced stereotype behavior in rats (in open field)-
MK-801 is an analogue of PCP which inhibits NMDA receptors and elicits hyperlocomotion and stereotypic behavior in rodents and is used as an animal model of schizophrenia (Stephen, et al., Topiramate antagonizes MK-801 in an animal model of schizophrenia, Eur. J. Pharmacol. 449, 2002, 121-5). For experimentation, naϊve Balb/c mice were used. MK-801 (0.15mg/kg i.p) was administered 40 minutes after Compound 1 (or any one of the other compounds of the invention) or a vehicle, and 20 minutes prior to placing the mouse in an open field.
Animals placed in the open field were followed for 60 minutes and their distance moved, velocity, duration of immobility, and number of rearing events were registered using the Noldus system.
As stated above, MK-801 inhibits NMDA receptors and elicits hyperlocomotion. Therefore, where an antagonism of the hyperactivity-induced by the MK-801 is observed upon administration of a compound of the invention, it is an indication as to the positive modulation of the NMDA activity. In other words, such a compound may be considered as useful in the treatment of schizophrenia. Catalepsy
Catalepsy in mice and rats serves as a behavioral model for the manifestation of the extrapyramidal adverse effects of neuroleptics (Worm, et al., Dopamine-like activities of an aminopyridazine derivative, CM 30366. A behavioral study, Naunyn- Schmeideberg's Arch Pharmacol, 334, 246-52, 1986).
Catalepsy in mice is evaluated using a bar test. The mice were placed in the middle of a steel rod situated between two platforms with their front paws resting on the bar. Animals were injected i.p. with a vehicle or Compound 1. Animals were scored 90 minutes later for the time it took each animal to reach the platform.
The elevated plus maze
The elevated plus maze is a widely used method to test anxiety in rodents (Pellow, et al., Pharmacol. Biochem. Behav., 24, 525-529 (1986)). The apparatus was made of wood and painted black, with two opposing open arms and two opposite enclosed arms of the same size. The arms were attached to a central square shaped in a plus sign. The whole apparatus was placed 50 cm above the floor. Anxious animals refrain from entering the open arm and prefer the closed arm. Benzodiazepines were shown to increase the time spent in the open arms and the frequency of entries to the open arms (Pellow, et al., Validation of openxlosed arm entries in an elevated plus- maze as a measure of anxiety in the rat, J. Neurosci. Methods, 14, 149-167 (1985)).
In a typical experiment, Balb/c male mice were administered orally with 10 and 20 mg/kg of Compound 1 or Compound 6 and with a vehicle or with diazepam (lmg/kg) administered per os (p.o.) 90 minutes before they were placed in the center of the maze. The frequency to the open arms, the time spent in the different arms, the velocity and number of rearings of the animals in each zone were recorded (Noldus). Mice treated with a compound of the invention and exhibit preference of entering to the open arms, or the center, and demonstrate a decrease in the time spent in the closed arms, are indicative of anxiolytic activity imposed by the compound.
The Morris Water Maze
The Morris Water Maze is a well known test aimed to assess spatial cognitive tasks (Anger, et al., Animal test systems to study behavioral dysfunctions of neurodegenerative disorders, Neurotoxicology, 12, 403-13 (1991)). The maze consists of a circular pool measuring 1.80 m in diameter 60 cm in height. The pool was filled with water (21±1°C) to a depth of 30 cm. A circular hidden escape platform (10 cm in diameter) was placed just below the water surface. The test room contained several permanent extra maze cues such as the rat housing rack, laboratory table, posters on the walls, etc.
C. RESULTS AND DISCUSSION
The effect of Compound 1 on the behavior of mice in the open field and the dose-dependent effect following i.p administration were evaluated. Naϊve male Mice (Balb/c, Harlan Israel) were used. The animals, divided 3 to 5 animals per group, were administered with Compound 1 (12.5, 25, 50, 75 and 100mg/kg) lhr prior to placing each in an open field. Mice were monitored for lhr (every 5 minutes) using the Noldus system, and their distance moved, velocity, time of immobility and number of rearings was recorded.
As Figs. IA-D indicate, Compound 1 induced a dose dependent decrease in the horizontal and vertical motility of the mice. At 12.5 mg/kg the drug did not modify significantly neither parameter and tended to increase rearing frequency. Moreover, doses up to 50mg/kg induced a mild inhibition of the horizontal and the vertical motility. Higher doses showed a marked sedative effect and motility was reduced to minimum.
The effect of Compound 6 on the behavior of mice in the open field was also examined. Naϊve male mice (Balb/c, Harlan Israel) were used. Animals (6 per group) were administered with Compound 6 (12.5, 25 and 50 mg/kg, i.p.) lhr prior to placing each in the open field. Mice were followed for lhr (every 5 minutes) using the Noldus system, and their distance moved, velocity, time of immobility and number of rearings was recorded.
As Figs. 2A-D show, Compound 6 induced a dose dependent decrease in the motility of the mice expressed by decreased distance moved and velocity. The effect was mild up to 50mg/kg. Compound 6 induced inhibition of the horizontal (distance) and the vertical motility (number of rearings). The drug increased the duration of "not moving" periods at all doses. It can thus be concluded that Compound 6 as is the case with Compound 1 has a mild sedative effect, as reflected by decreasing horizontal and vertical activity, mainly due to increased periods of immobility. The effect of Compound 6 on the distance moved in Balb/c mice exposed to MK-801 (15mg/kg) i.p. and to Compound 6 (up to 12.5mg/kg, i.p.) administered lhr prior to MK-801 was also tested. The results indicate that Compound 6 did not cause a consistent dose dependent effect on the motility of the MK-801 treated mice. The data suggests that Compound 6 is a mild agent for the treatment of glutamate NMDA hypoactivity.
The effect of oral administration of Compound 1 in the open field was tested by orally administering to male ICR mice varying amounts of Compound 1 (5, 10 and 20 mg/kg) or vehicle. Animals were placed in the open field 1 hr after drug administration and horizontal and vertical behavior was recorded for 20 minutes.
As Figs. 3A-C show, oral administration of Compound 1 at 10 and 20mg/kg slightly decreased the horizontal behavior as evidenced by the decrease in velocity and distance moved, and increased the vertical behavior as evidenced by increase in the number of rearings. It seems that the decreased velocity and distance moved are related to more time that the animal spent in the vertical position. The data also suggests that Compound 1 induces a slight increase in vigilance and/or stimulation; this effect may also be relevant to a stimulatory effect on cognition and learning.
The dose-dependent effect of Compound 3 administered i.p. in the open field was also tested. Naϊve male mice (Balb/c, Harlan Israel) were used. Animals were administered with Compound 3 (12.5, 25 and 50 mg/kg, i.p., 6 per group) lhr prior to placing each in the open field. Mice were followed for lhr (every 5 minutes) using the Noldus system, and their distance moved, velocity, time of immobility and number of rearings was recorded.
Figs. 4A-C show the behavioral parameters of Compound 3 in the open field. Compound 3 induced a mild decrease in the motility of the mice expressed by decreased distance moved and velocity up to 25mg/kg and a marked decrease in the motility parameters at 50mg/kg (Fig. 4A). The drag dose dependently increased the duration of "not moving" periods (Fig. 4B) and decreased the number of rearings vs. controls (Fig. 4C). Comparison between Compound 1, Olanzapine or D-serine on anxiety parameters in mice in the open field paradigm
The effect of Compound 1, olanzapine and D-Serine [20mg/kg, orally), administered lhr before placing the male ICR mice in the open field on anxiety parameters was examined in an open filed of the construction shown above. Animals were administered orally with Compound 1 (5, 10 and 20 mg/kg) or with a vehicle. Animals were placed in the open field 1 hr after drug administration and animal track was registered for 20 minutes. The time spent in the center (zone 3) and the frequency to the center were indicators of anxiety. High frequency and duration in the center indicated anxiolytic activity.
The results shown in Fig. 5 suggest that Compound 1 possesses anxiolytic activity which differs from olanzapine or D-serine.
Amphetamine-induced hyperactivity and stereotypic behavior in mice
As stated above, the amphetamine— induced hyperactivity and motility is one of the most popular animal models for schizophrenia. The experiment was conducted with ICR male mice placed in individual barrels. Compound 1 (20mg/kg) was administered p.o to the mice lhr prior to i.p. administration of amphetamine (2.mg/kg). The hyperactive behavior expressed by the number of climbings and rearings and the stereotypic behavior expressed by the number of head movements was recorded every 15 minutes over a period of Ih.
As Figs. 6A-B show, Compound 1 was effective in antagonizing hyperactivity- induced by amphetamine. On the other hand, Compound 1 alone increased the rearing behavior as compared to control animals. Similar results were obtained also in the open field experiment. Moreover, Compound 1 did not attenuate the increase in head movements-induced by amphetamine. Overall, the data suggests a partial antagonist effect of Compound 1 at low doses against amphetamine-induced hyperactivity. High efficacy was found in antagonizing increased motility, without affecting the stereotypic behavior. These data point for an efficacy of Compound 1 against psychotic symptoms, without inducing extrapyramidal symptoms.
The effect of Compound 3 (12.5, 25 and 50 mg/kg, i.p.) on amphetamine- induced hyperactivity in Balb/c mice was also examined. Animals (6 per group) were injected with Compound 3 (12.5, 25 and 50mg/kg) and 30 minutes later received amphetatnine (2mg/kg ip). After 30 minutes, animals were exposed to an open field test for a period of 20 minutes. Results show that Compound 3 dose-dependently antagonized the effect of amphetamine and decreased hypermotility. Compound 3 combined with amphetamine dose-dependently increased immobility and was effective already at 12.5mg/kg, i.p. This indicates that Compound 3 is highly effective against hyper-domaminergic activity as manifested by amphetamine treatment.
Fig. 7A shows the effect of Compound 3 (12.5, 25 and 50mg/kg. i.p at -60 minutes) on distance moved. Results demonstrate a dose-dependent decrease in the distance moved with normalization at 12.5mg/kg and a marked decrease at higher doses. Fig. 7B shows the immobility time of amphetamine and amphetamine combined with Compound 3. The results show that amphetamine was similar to controls yet Compound 3 already at 12.5mg/kg antagonized the hyperactivity ensued by the amphetamine.
Overall, the results demonstrate a marked antidopaminergic activity for Compound 3, which may be useful for schizophrenia and related disorders therapy.
Effect of Compound 1 on MK801-induced hyperactivity in mice.
As stated above, MK-801 (an NMDA receptor antagonist) is a widely accepted animal model for schizophrenia. The experiment was conducted with Balb/c male mice (Harlan II), 6 per group. Compound 1 (50mg/kg) was administered i.p. (lhr before experimentation), to mice alone or combined with MK-801 (0.15mg/kg, i.p.) administered 20 minutes prior to placing the mice individually in an open field for 60 minutes. The hyper- active behavior expressed by hyperlocomotion, velocity, strong mobility, number of rearing was evaluated using the Noldus system, each point represents the mean+/- 6 determinations.
As Figs 8A-E show, at 50mg/kg Compound 1 induces a clear cut decrease in both basal and MK-801 -induced stimulation of horizontal motility as expressed by distance moved, velocity, strong mobility (which is expressed by moving the center of gravidance by more than 30%). Compound 1 also markedly suppressed vertical motility (number of rearings) alone and increased the inhibition of rearings presented by MK-801 as compared to controls. This suggests that Compound 1 has a significant positive modulation effect on the NMDA glutamate receptor. As Figs. 9A-B show, Compound 1 at 30 and 50mg/kg, i.p. inhibited in a dose related manner the hyperlocomotion effect of MK-801. Figs. 1OC and D show that Compound 1 at these concentrations did not modify the increased frequency to the center of animals treated with MK-801, and even increased the time spent in the center (zone 3). It can thus be concluded that Compound 1 at high doses antagonizes positive symptoms of MK-801 treated mice, without decreasing the anxiolytic activity of the drug.
Figs. 10A-D shows the effect of Compound 3 (12.5, 25 and 50 mg/kg, i.p.) on hyperactivity-induced by MK-801 (0.15mg/kg, i.p.) in Balb/c mice. The data shows that Compound 3 induced a dose dependent decrease in MK-801 -induced hyperactivity, a slight effect was observed with 7.5mg/kg, normalization of activity was achieved with 25mg/kg and sedation with 50mg/kg (Fig. 10A). Immobility was not found with the small and intermediate doses (25mg/kg) and appeared with the high dose (Fig. 10B). Compound 3 at the low dose tended to increase the frequency to the center of the field (Fig. 10C) and the time spent in the center (Fig. 10D). These results suggest a potential anxiolytic activity for Compound 3.
Effect of Compound 1 at 30-50 mg/kg on catalepsy in mice
As Fig. 11 shows, Compound 1 at doses of up to 50mg/kg did not induce catalepsy in mice. This suggests that at doses which are efficacious against positive symptoms of schizophrenia there is no catalepsy or extrapyramidal symptoms induced by Compound 1.
Effect of Compound 1 on the forced swim test (FST)
Males Balb/c mice (Harlan Israel) were used. Animals were administered orally with Compound 1 (10 or 20 mg/kg) or with a vehicle. The results shown in Figs. 12A- D and Figs. 13 A-C demonstrate that orally administered Compound 1 at 10mg/kg significantly increased the distance moved (swimming behavior) and strong mobility (climbing behavior) and at 20mg/kg decreased immobility as compared to vehicle treated animals. The results suggest a significant antidepressant activity for Compound 1 as appears in the forced swim test. Comparison between the activity of Compound 1 and Olanzapine
Males ICR mice were used. Animals were administered orally with olanzapine or Compound 1 (20 mg/kg) or with a vehicle. The results shown in Figs. 14A-B indicate that orally administered olanzapine at 20mg/kg significantly decreased distance moved, velocity and strong mobility (climbing) and increased immobility. Compound 1 at the same dose did not modify velocity and distance moved, and significantly decreased strong mobility (climbing) and immobility compared to vehicle and to olanzapine in treated animals. These data suggest that Compound 1 is different from olanzapine, and at 20 mg/kg it causes decrease in immobility, suggesting a potential antidepressant activity.
Effect of Compound 1 on anxiety in the elevated plus maze
Male Balb/c mice were used. Animals were transferred to the behavior room 24 hr before the experiment. Compound 1 or diazepam were administered orally 90 minutes before testing. Each treatment group included 5 animals. Fig. 15A shows the effect of Compound 1 on frequency of the mice to the different arms. The results show that mice treated with Compound 1 (20mg/kg) frequented significantly more the open arm and the center resembling the mice treated with diazepam at lmg/kg. Fig. 15B shows the effect of Compound 1 on duration of time spent in the different zones of the elevated plus maze. At 20mg/kg Compound 1 increased the time spent in the center, but did not significantly affect the time spent in the closed and the open arm at variance from diazepam. Fig. 15C shows the velocity of the mice which was higher in the mice treated with diazepam but not in the mice treated with Compound 1.
Fig. 15D shows the frequency of rearings of mice treated with Compound 1, diazepam or controls. The results show increased number of rearings in the open arm in the diazepam and the Compound 1 treated groups. As may be noted, diazepam significantly increased the number of rearings also in the center.
From the above it may be concluded that at 20mg/kg Compound 1 showed anxiolytic activity which resembles diazepam, but differs from it in its intensity and in the effects on velocity.
Fig. 15E shows the total time spent by the mice administered with Compound 6 (3, 9 and 27 mg/kg, orally) on the different arms of the maze. The results demonstrate that mice treated with Compound 6 spent more time on the open arms and less on the center, suggesting a potential anxiolytic activity for the Compound.
Effect of Compound 1 on spatial cognition in the Morris Water Maze
The Morris Water Maze is a well known test aimed to assess spatial cognitive tasks. The maze consists of a circular pool measuring 1.80 m in diameter 60 cm in height. The pool was filled with water (21±1°C) to a depth of 30 cm. A circular hidden escape platform (10 cm in diameter) was placed just below the water surface. The test room contained several permanent extra maze cues such as the rat housing rack, laboratory table, posters on the walls, etc.
In the experiment rats were given Compound 1 orally on day 1 and the first test begun 90 minute later, six trials per day, for 3 consecutive days, to find the hidden platform (acquisition phase). The escape latency, i.e., the time required by the rat to find and climb onto the platform, was recorded for up to 120 sec. Each rat was allowed to remain on the platform for 30 sec, after which it was removed to its home cage. If the rat did not find the platform within 120 sec, it was manually placed on it and returned to its home cage after 30 sec.
A video camera was placed above the center of the pool for tracking the rat, and a video tracking system (Noldus) with online digital output directly fed data into a computer. Data were analyzed using Etho Vision automated tracking system software (Noldus).
Fig. 16 shows the effect of 10 and 20 mg/kg of Compound 1, administered po, on latency to platform. Compound 1 at 20mg/kg showed a faster learning on the first day of the spatial task and reached the platform earlier. Also on the second day, an improvement was noticed of task execution by mice treated with Compound 1 (20mg/kg). On the third day, no difference was found between all groups, and all rats reached rapidly the platform. These results clearly suggest that Compound 1 can enhance cognitive tasks in the rats.
Fig. 17 shows the effect of acute use of Compound 1 at 10 and 20 mg/kg given p.o. on day 1 on the spatial cognitive tasks in the Morris Water Maze in rats pretreated (-30 minutes) with MK-801 (on day 1) at 0.15 mg/kg, i.p. MK-801 alone induced a significant impairment in the memory tasks of the rats as expressed by increased latency to the platform as compared to the normal controls. Compound 1 at both doses decreased the latency to the platform on day 3 of the experiment but not on days 1 and 2. These results may thus provide an indication as to the ability of Compound 1 to relief some of the cognitive impairments observed in states of schizophrenia due to decreased NMDA activity.
The relief of cognitive impairments was also shown in the use of Compound 6. Fig. 18 shows the effect of acute use of Compound 6 at 10 mg/kg given p.o. once on day 1 on the spatial cognitive tasks in the Morris Water Maze in rats pretreated (-30 minutes) with MK-801 (0.15 mg/kg, i.p.). MK-801 alone induced a significant impairment in the memory tasks of the rats as expressed by increased latency to the platform as compared to the normal controls. Compound 6 at 10 mg/kg decreased the latency to the platform on days 2 and 3 of the experimentation. In similarity with Compound I5 the described use of Compound 6 suggests use in relieving some of the cognitive impairments seen in states of schizophrenia due to decreased NMDA activity.
Overall and without wishing to be bound by theory, the effects of Compound 1 and 6 on spatial memory suggest a common mechanism for both effective activity on NMDA blockage and dopamine overshooting, and parallel stimulation of negative symptoms associated with cognitive impairment.
Effect of Compound 6 on anxiety in the EPM apparatus
Male Balb/c mice were used. Animals were transferred to the behavior room 24hr before the experiment. Compound 6 (3, 9, or 27 mg/kg) or vehicle were adrninistered orally 90 minutes before testing. Each treatment group included 5 animals. The effect of Compound 6 on duration of time spent in the different zones of the elevated plus maze is evident from the dose-dependently increase in the time spent in the open arms and decrease in the time spent in the center. The drug did not significantly affect the time spent in the closed arm. This suggests that Compound 6 has an anxiolytic activity.
Subchronic Toxicity
Subchronic toxicity was tested in ICR male mice. Animals (5 per group) received Compound 1 daily (10 and 20mg/kg p.o). Animals were followed up for 7 days; weight, food intake and water intake were registered. As shown in Fig. 19, no difference compared to control animals in body weight, food intake and water intake was found.
The drug was well tolerated, and no apparent difference was found also in animal general behavior. Further results showed that Compound 1 did not cause toxic effect up to 20mg/kg given for 7 days.
Ϊn-Vitro Toxicity
Since glutamate is known to possess a neurotoxic effect, the in-vitro effect of Compound 1 was evaluated as compared to olanzapine, paroxetine and sertraline on human glioma U83 cell viability. Cells were treated with Compound 1, olanzapine, paroxetine, or sertraline as compared to controls (saline treated cells), 24hr after exposure to the drug. Determination of cell viability was performed in cells (10,000/well) using neutral red method. Absorption of neutral red by lysosomes caused coloring of living cells. Quantitative analysis was performed by colorimetric assay (ELISA reader at 550 nin).
The results shown in Fig. 20 demonstrate that Compound 1 is not toxic up to lOOμM to human glioma cells. Olanzapine, sertraline and paroxetine at concentrations higher than 30μM induced a dose dependent decrease in cell viability. Overall, the results suggest that Compound 1 as the other compounds of the invention are well tolerated and possess low toxicity as presented by the in vivo and the in vitro assays detailed herein.

Claims

CLAIMS:
1. A compound of the general formula L-M-V, wherein
L is a central nervous system (CNS) active moiety derived from a CNS active compound selected from an anticonvulsant drug, an anti-Parkinsonian drug, an opioid and non-opioid analgesic, an appetite suppressant, an anti-emetic, an analgesic- antipyretic, a stimulant, an antidepressant, an antimanic agent, an antianxiety agent, an antipsychotic agent, a sedative and a hypnotic;
M is a linker selected from -NH-, -NH2 +-, -O-, -S-, CrQ-alkylene, C3-C8- cycloalkylene, -CH2-O-CH2, -(CH2)n-O-(CH2)n-, -(CH2-O)n-, and -(CH2CH2-O)n-, said alkylene and cycloalkylene may optionally be substituted by one or more group selected from C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl;
V is a modulator of the glutamate N-methyl-D-aspartate (NMDA) receptor selected from an amino acid, or ester, or amide, or alkylated amine of the amino acid; and each of n, independently of each other, is an integer between zero and 3; including a salt, a prodrug, or a stereoisomer thereof.
2. A compound of the general formula L-M-V, wherein L is a central nervous system (CNS) active moiety; M is a linker; and
V is a modulator of the glutamate N-methyl-D-aspartate (NMDA) receptor; including a salt, a prodrug, or a stereoisomer thereof.
3. The compound according to claim 2, wherein said CNS active moiety is derived from CNS active compounds selected from an anticonvulsant drug, an anti-Parkinsonian drug, an opioid and non-opioid analgesic, an appetite suppressant, an anti-emetic, an analgesic-antipyretic, a stimulant, an antidepressant, an antimanic agent, an antianxiety agent, an antipsychotic agent, a sedative and a hypnotic.
4. The compound according to claim 1 or 3, wherein said CNS active' moiety is derived from an anti-depressant compound selected from anti-unipolar agents and anti- bipolar agents.
5. The compound according to claim 4, wherein said anti-unipolar agent is selected from fluoxetine, fiuvoxamine, desipramine, paroxetine and sertraline.
6. The compound according to claim 4, wherein said anti-bipolar agent is selected from remoxipride, alizapride, clozapine, olanzapine and quetiapine.
7. The compound according to claim 1 or 3, wherein said anti-psychotic agent is selected from clozapine, olanzapine, quetiapine, loxapine, risperidone, flupenthixol, thioridazine, chlorpromazine, perphenazine, fluphenazine, zuclopenthixol, spiperone, amisulpride, sulpiride, remoxipride and alizapride.
8. The compound according to claim 1 or 3, wherein said anti-anxiety agent is selected from fluoxetine, fluvoxamine, desipramine, paroxetine and sertraline.
9. The compound according to claim 2, wherein said CNS active moiety is derived from a CNS active compound selected from a monocyclic, a bicyclic and a tricyclic anti-psychotic agent.
10. The compound according to claim 9, wherein said monocyclic agent is selected from amisulpride, sulpiride.
11. The compound according to claim 9, wherein said bicyclic agent is selected from spiperone, remoxipride, alizapride.
12. The compound according to claim 9, wherein said tricyclic agent is selected from chlorpromazine, perphenazine, fluphenazine, zuclopenthixol, clozapine, olanzapine, quetiapine, loxapine, flupenthixol and thioridazine.
13. The compound according to claim 2, wherein said CNS active moiety is derived from clozapine, olanzapine, or quetiapine.
14. The compound according to claim 2, wherein said linker, M, is selected from -NH-, -NH2 +-, -O-, -S-, Ci-C8-alkylene, C3-C8-cycloalkylene, -CH2-O-CH2, -(CH2VO- (CH2)IT, -(CH2-O)n-, and -(CH2CH2-O)n-, wherein said alkylene and cycloalkylene may optionally be substituted by one or more group selected from C1-C4 alkyl, C2-C4 alkenyl, and C2-C4 alkynyl, and wherein each of n, independently of each other, is an integer between zero and 3.
15. The compound according to claim 1 or 14, wherein said linker is selected from -NH-, -O-, -S-, -(CH2)m- wherein m is an integer between 1 and 8, -(CH2-CH=CH- CH2)-, -(CH=CH2-CH2-CH2)-, -(CH2-CH=CH-CH2-CH2-CH2)-, -(CH2-C-C-CH2)-, - (C=C-CH2-CH2)-, -(CH2-NH-CH=CH-CH2)-, -(CH2-NH-CH2-CH2-CH2)-, -(CH2-O- CH2-CH2)-, -(CH2VO-CCH2V, -CH2-O-CH2, -(CH2-O)n-, and -(CH2CH2-O)n- wherein n is an integer between 0 and 3, and substituted derivatives thereof.
16. The compound according to claim 2, wherein said modulator of the glutamate NMDA receptor, V, is an amino acid, or ester, or amide, or alkylated amine thereof.
17. The compound according to claim 1 or 16, wherein said amino acid is selected from glycinyl, sarcosinyl, serinyl and cysteinyl.
18. The compound according to claim 17, wherein said amino acid is an ester or an amide of an amino acid selected from glycinyl, sarcosinyl, serinyl and cysteinyl.
19. The compound according to claim 1 or 2, wherein the bonds between M and L and between M and V are non-hydrolizable.
20. The compound according to claim 1 or 2, wherein CNS active moiety is derived from a tricyclic anti-psychotic agent of the general formula (A):
Figure imgf000062_0001
Formula (A) wherein
X is selected from -NH-, -O- and -S-;
Y is selected from -C=C-, -NH-, -O-, and -S-; and
Z and Z' are each independently selected from C1-C4-alkyl and halide (I, Br, Cl and F).
21. The compound according to claim 20, being of the formula (I):
Figure imgf000063_0001
Formula (I) wherein M and V are as defined in claim 2.
22. The compound according to claim 21, wherein V is glycinyl, or an ester thereof, and the compound is of the formula (Ia):
Figure imgf000063_0002
Formula (Ia)
wherein
M is selected from null, -NH-, -O, -S-, Ci-Cg-alkyl, C3-C8-cycloalkyl, -CH2-O- CH2-, -(CH2-O)n-, and -(CH2CH2-O)n-, n is an integer between O and 3, and R is selected from H and a C1-C4 alkyl.
23. The compound according to claim 22, being a compound selected from compounds herein designated Compound 1, Compound 2, Compound 3, and Compound 4.
24. The compound according to claim 21, wherein V is selected from sarcosinyl or an ester thereof and serinyl or an ester thereof.
25. The compound according to claim 24, being a compound of formula (Ib):
Figure imgf000064_0001
Formula (Ib)
wherein
M is selected from null, -NH-, -O-, -S-, Ci-Cg-alkyl, C3-C8-cycloalkyl, -CH2-O- CH2-, -(CH2-O)n-, and -(CH2CH2-O)n-, n is an integer between O and 3,
R and R', independently of each other are selected from H and a C1-C4-alkyl, and R" is selected from H and -CH2OH.
26. The compound according to claim 25, wherein M is absent, R" is H and R' is selected from H and a C1-C4 alkyl.
27. The compound according to claim 26, being selected from compounds herein designated Compound 5 through Compound 10.
28. The compound according to claim 25, wherein M is selected from -CH2-O-CH2, -(CH2-O)n-, and -(CH2CH2-O)n-, wherein n is an integer between O and 3.
29. The compound according to claim 28, being selected from compounds herein designated Compound 11 through Compound 13.
30. The compound according to claim 1 or 2, being a compound selected from compounds herein designated Compound 1 through Compound 54.
31. A use of at least one compound according to any one of claims 1 to 30 for the preparation of a composition.
32. The use according to claim 31, wherein said composition is a pharmaceutical composition.
33. Use of a compound according to any one of claims 1 to 30 for treating a disease or disorder.
34. A composition comprising at least one compound according to any one of claims 1 to 30; and a carrier.
35. The composition according to claim 34, being a pharmaceutical composition.
36. The composition according to claim 35, being suitable for oral, aerosol, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal, or vaginal administration.
37. The composition according to claim 35 or 36, for treating a psychological or psychiatric disease or disorder.
38. The composition according to claim 37, wherein said psychological or psychiatric disease or disorder is associated with the glutamate NMDA receptor.
39. The composition according to claim 37 or 38, wherein said disease or disorder is selected from a psychotic disorder, an anxiety disorder, a dissociative disorder, a personality disorder, a mood disorder, an effective disorder, a neurodegenerative disorder, a convulsive disorder, a boarder line disorder and a mental disease or disorder.
40. The composition according to claim 39, wherein said disease or disorder is selected from schizophrenia, bipolar disorders, psychotic depression, delussional disorders, conduct disorders, psychosis-induced dementia, organic psychosis, mood disorders, Torte's syndrome, depression, post-traumatic stress disorder, anxiety, panic disorder and Alzheimer's disease.
41. The composition according to claim 40, wherein, said disease or disorder is selected from schizophrenia, anxiety, and depression.
42. A method for treating a disease or disorder comprising administering to a subject in need thereof a compound according to any one of claims 1 to 30 or a composition according to any one of claims 35 to 41.
43. A method of modulating the activity of the glutamate NMDA receptor, said method comprising contacting a tissue expressing said glutamate NMDA receptor with at least one compound according to any one of claim 1 to 30 or a composition according to claims 35 to 41.
44. A method for modulating one or more biological and/or pharmacological pathway, whereby said modulation ensues the treatment of an at least one psychological and/or psychiatric disease or disorder or the preventing of such a disease or disorder, said method comprising administering to a subject an effective amount of a compound according to any one of claims 1 to 30 or a composition according to any one of claims 35 to 41.
45. A method for treating schizophrenia, said method comprising administering to a person suffering from schizophrenia or symptoms associates therewith an effective amount of a compound according to any one of claims 1 to 30 or a composition according to any one of claims 35 to 41.
PCT/IL2007/001296 2006-10-25 2007-10-25 Novel psychotropic agents having glutamate nmda activity WO2008050341A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN2007800480740A CN101636182B (en) 2006-10-25 2007-10-25 Novel psychotropic agents having glutamate NMDA activity
JP2009534053A JP2010507648A (en) 2006-10-25 2007-10-25 Novel psychotropic drug with glutamic acid NMDA activity
EP07827270.5A EP2077860B1 (en) 2006-10-25 2007-10-25 Psychotropic agents having glutamate nmda activity
US12/447,381 US8394790B2 (en) 2006-10-25 2007-10-25 Psychotropic agents having glutamate NMDA activity
IL198331A IL198331A (en) 2006-10-25 2009-04-23 Psychotropic agents having glutamate nmda activity
US13/748,861 US8828993B2 (en) 2006-10-25 2013-01-24 Psychotropic agents having glutamate NMDA activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85409106P 2006-10-25 2006-10-25
US60/854,091 2006-10-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/447,381 A-371-Of-International US8394790B2 (en) 2006-10-25 2007-10-25 Psychotropic agents having glutamate NMDA activity
US13/748,861 Division US8828993B2 (en) 2006-10-25 2013-01-24 Psychotropic agents having glutamate NMDA activity

Publications (2)

Publication Number Publication Date
WO2008050341A2 true WO2008050341A2 (en) 2008-05-02
WO2008050341A3 WO2008050341A3 (en) 2008-06-19

Family

ID=38947404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/001296 WO2008050341A2 (en) 2006-10-25 2007-10-25 Novel psychotropic agents having glutamate nmda activity

Country Status (5)

Country Link
US (2) US8394790B2 (en)
EP (1) EP2077860B1 (en)
JP (1) JP2010507648A (en)
CN (1) CN101636182B (en)
WO (1) WO2008050341A2 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009106848A2 (en) * 2008-02-29 2009-09-03 Chroma Therapeutics Ltd. Enzyme and receptor modulation
WO2011082076A1 (en) 2009-12-31 2011-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US8900604B2 (en) 2010-03-11 2014-12-02 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US9850318B2 (en) 2012-08-21 2017-12-26 Janssen Pharmaceutica Nv Antibodies to quetiapine haptens and use thereof
US10288631B2 (en) 2012-08-21 2019-05-14 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10370457B2 (en) 2012-08-21 2019-08-06 Janssen Pharmaceutica Nv Antibodies to paliperidone haptens and use thereof
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US10379129B2 (en) 2012-08-21 2019-08-13 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10690686B2 (en) 2012-08-21 2020-06-23 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
EP2888590B1 (en) * 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
US10793644B2 (en) 2012-08-21 2020-10-06 Janssen Pharmaceutica Nv Antibodies to risperidone haptens and use thereof
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11377421B2 (en) 2016-11-28 2022-07-05 Lb Pharmaceuticals Inc. Psychotropic agents and uses thereof
JP6968899B2 (en) 2016-11-28 2021-11-17 エルビー・ファーマシューティカルズ・インコーポレイテッド Psychotropic drugs and their use
CN110627735A (en) * 2018-06-25 2019-12-31 江阴安博生物医药有限公司 Novel quetiapine analogue and preparation method and application thereof
CN114685527B (en) * 2020-12-25 2024-03-05 长沙博源医疗科技有限公司 Olanzapine derivative, immunogen, anti-olanzapine specific antibody, preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638931A4 (en) * 2003-06-11 2007-11-07 Neuromolecular Inc Method of targeting a therapeutic agent
CA2576530A1 (en) * 2004-08-11 2006-02-23 Donald L. Barbeau Noncardiotoxic pharmaceutical compounds
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2007065036A2 (en) 2005-12-02 2007-06-07 Neuromolecular Pharmaceuticals, Inc. Therapeutic conjugates and methods of using same
WO2008042634A2 (en) * 2006-09-29 2008-04-10 Janssen Pharmaceutica, N.V. Isotopically labeled trapping agent and method for identifying reactive metabolites

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009219926B2 (en) * 2008-02-29 2014-04-17 Macrophage Pharma Limited Intracellular enzyme and receptor modulation
WO2009106848A3 (en) * 2008-02-29 2010-05-14 Chroma Therapeutics Ltd. Intracellular enzyme and receptor modulation
WO2009106848A2 (en) * 2008-02-29 2009-09-03 Chroma Therapeutics Ltd. Enzyme and receptor modulation
US9636409B2 (en) 2008-02-29 2017-05-02 Glaxosmithkline Intellectual Property Development Limited Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters
EA019838B1 (en) * 2008-02-29 2014-06-30 Хрома Терапьютикс Лтд. COVALENT CONJUGATES OF α,α-DISUBSTITUTED GLYCINE ESTER AND MODULATOR OF ACTIVITY OF INTRACELLURAR ENZYME OR RECEPTOR
JP2013516414A (en) * 2009-12-31 2013-05-13 ケムファーム・インコーポレーテッド Amino acid conjugate of quetiapine, its production and use
EP2987789A1 (en) * 2009-12-31 2016-02-24 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US10010615B2 (en) 2009-12-31 2018-07-03 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
JP2014159462A (en) * 2009-12-31 2014-09-04 Kempharm Inc Amino acid conjugates of quetiapine, process for making and using the same
WO2011082076A1 (en) 2009-12-31 2011-07-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
CN104586859A (en) * 2009-12-31 2015-05-06 凯姆制药公司 Amino acid conjugates of quetiapine, process for making and using the same
EP2519101A4 (en) * 2009-12-31 2013-06-26 Kempharm Inc Amino acid conjugates of quetiapine, process for making and using the same
EP2519101A1 (en) * 2009-12-31 2012-11-07 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US9597403B2 (en) 2009-12-31 2017-03-21 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US9511149B2 (en) 2010-03-11 2016-12-06 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8900604B2 (en) 2010-03-11 2014-12-02 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US9889198B2 (en) 2010-03-11 2018-02-13 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US9890150B2 (en) 2010-03-11 2018-02-13 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US10793644B2 (en) 2012-08-21 2020-10-06 Janssen Pharmaceutica Nv Antibodies to risperidone haptens and use thereof
US10690686B2 (en) 2012-08-21 2020-06-23 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10370457B2 (en) 2012-08-21 2019-08-06 Janssen Pharmaceutica Nv Antibodies to paliperidone haptens and use thereof
US11225527B2 (en) 2012-08-21 2022-01-18 Janssen Pharmaceutica Nv Antibodies to paliperidone haptens and use thereof
US10379129B2 (en) 2012-08-21 2019-08-13 Janssen Pharmaceutica Nv Antibodies to paliperidone and use thereof
US9850318B2 (en) 2012-08-21 2017-12-26 Janssen Pharmaceutica Nv Antibodies to quetiapine haptens and use thereof
EP2888590B1 (en) * 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
US10288631B2 (en) 2012-08-21 2019-05-14 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10465013B2 (en) 2012-08-21 2019-11-05 Janssen Pharmaceutica Nv Antibodies to quetiapine haptens and use thereof
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US10852313B2 (en) 2015-12-17 2020-12-01 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US11104742B2 (en) 2015-12-17 2021-08-31 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10435478B2 (en) 2015-12-17 2019-10-08 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
US10577317B2 (en) 2017-12-05 2020-03-03 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US10800738B2 (en) 2017-12-05 2020-10-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US10576058B2 (en) 2017-12-05 2020-03-03 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US10874639B2 (en) 2017-12-05 2020-12-29 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US10660875B1 (en) 2017-12-05 2020-05-26 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US11370753B2 (en) 2017-12-05 2022-06-28 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11517558B2 (en) 2017-12-05 2022-12-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US11767293B2 (en) 2017-12-05 2023-09-26 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US11160758B2 (en) 2019-06-04 2021-11-02 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US11654113B2 (en) 2019-06-04 2023-05-23 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Also Published As

Publication number Publication date
WO2008050341A3 (en) 2008-06-19
US20100093704A1 (en) 2010-04-15
US8394790B2 (en) 2013-03-12
US20130131048A1 (en) 2013-05-23
EP2077860A2 (en) 2009-07-15
EP2077860B1 (en) 2014-04-09
CN101636182A (en) 2010-01-27
US8828993B2 (en) 2014-09-09
CN101636182B (en) 2013-01-16
JP2010507648A (en) 2010-03-11

Similar Documents

Publication Publication Date Title
EP2077860B1 (en) Psychotropic agents having glutamate nmda activity
US10478412B2 (en) GABA conjugates and methods of use thereof
JP6177832B2 (en) Arginase inhibitors and methods of use
US20110190267A1 (en) Prodrugs of opioids and uses thereof
WO2010081036A2 (en) Fluorine containing compounds and methods of use thereof
US20020160988A1 (en) Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20180016276A1 (en) Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
Harikandei et al. Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives
FI86845C (en) PROCEDURE FOR THE FRAMEWORK OF FLUORALLYLAMIN THERAPEUTIC
US20110257111A1 (en) Hydroxyethlamino Sulfonamide Derivatives
CA2922190A1 (en) Mao-b selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof
CA2868447C (en) Cyclic prodrugs of duocarmycin analogs
IL198331A (en) Psychotropic agents having glutamate nmda activity
WO2007020631A2 (en) Tetracyclic benzofuran derivatives with therapeutic activities
US20220213128A1 (en) L-Dopa Enhanced with a Neuroprotective Agent as a Therapy for Parkinson's Disease
US20180305292A1 (en) Derivatives of nonsteroidal anti-inflammatory drugs
JP2004517106A (en) Use of a compound that restores the active ingredient in vivo as a drug
Corelli et al. Chemistry of GABA B Receptor Ligands: Focus on Agonists and Antagonists
CA3229910A1 (en) Fluorinated empathogens
CA3230779A1 (en) Asymmetric allyl tryptamines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048074.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827270

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 198331

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2009534053

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007827270

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1015/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12447381

Country of ref document: US